QuantumScape (QS) 10-K 28 Feb 23 2022 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($) $ in Billions	12 Months Ended
	Dec. 31, 2022	Feb. 21, 2023	Jun. 30, 2022
Document And Entity Information [Line Items]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2022
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	FY
Document Annual Report	true
Document Transition Report	false
Entity Registrant Name	QUANTUMSCAPE CORPORATION
Entity Central Index Key	0001811414
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Emerging Growth Company	false
Entity Small Business	false
ICFR Auditor Attestation Flag	true
Entity Shell Company	false
Entity Incorporation, State or Country Code	DE
Entity File Number	001-39345
Entity Tax Identification Number	85-0796578
Entity Address, Address Line One	1730 Technology Drive
Entity Address, City or Town	San Jose
Entity Address, State or Province	CA
Entity Address Postal Zip Code	95110
City Area Code	408
Local Phone Number	452-2000
Entity Public Float			$ 2.2
Title of 12(b) Security	Class A Common Stock, par value $0.0001 per share
Trading Symbol	QS
Security Exchange Name	NYSE
Documents Incorporated by Reference	DOCUMENTS INCORPORATED BY REFERENCE Portions of the registrant’s definitive proxy statement relating to its annual meeting of stockholders to be held in 2023, to be filed with the Securities and Exchange Commission within 120 days after the end of the fiscal year to which this Annual Report on Form 10-K relates, are incorporated herein by reference in Part III where indicated. Except with respect to information specifically incorporated by reference in this Annual Report on Form 10-K, such proxy statement is not deemed to be filed as part hereof.
Auditor Name	Ernst & Young LLP
Auditor Location	San Jose, California
Auditor Firm ID	42
Class A Common Stock
Document And Entity Information [Line Items]
Entity Common Stock, Shares Outstanding		360,515,533
Class B Common Stock
Document And Entity Information [Line Items]
Entity Common Stock, Shares Outstanding		79,454,147

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Current assets
Cash and cash equivalents ($3,395 and $3,382 as of December 31, 2022 and 2021, respectively, for joint venture)	$ 235,393	$ 320,700
Marketable securities	826,340	1,126,975
Prepaid expenses and other current assets	10,591	15,757
Total current assets	1,072,324	1,463,432
Property and equipment, net	295,934	166,183
Right-of-use assets - finance lease	28,013	30,886
Right-of-use assets - operating lease	60,782	36,913
Other assets	18,353	18,234
Total assets	1,475,406	1,715,648
Current liabilities
Accounts payable	21,420	14,182
Accrued liabilities	7,477	6,078
Accrued compensation and benefits	13,061	9,119
Operating lease liability, short-term	3,478	1,209
Finance lease liability, short-term	1,373	19
Total current liabilities	46,809	30,607
Operating lease liability, long-term	62,560	36,760
Finance lease liability, long-term	38,005	39,378
Other liabilities	8,488	315
Total liabilities	155,862	107,060
Commitment and contingencies (see Note 7)
Redeemable non-controlling interest	1,704	1,693
Stockholders’ equity
Preferred stock- $0.0001 par value; 100,000 shares authorized, none issued and outstanding at December 31, 2022 and 2021
Common stock - $0.0001 par value; 1,250,000 shares authorized (1,000,000 Class A and 250,000 Class B); 358,505 Class A and 79,454 Class B shares issued and outstanding at December 31, 2022, 332,869 Class A and 95,450 Class B shares issued and outstanding at December 31, 2021	44	43
Additional paid-in-capital	3,771,181	3,634,665
Accumulated other comprehensive loss	(17,873)	(4,208)
Accumulated deficit	(2,435,512)	(2,023,605)
Total stockholders’ equity	1,317,840	1,606,895
Total liabilities, redeemable non-controlling interest and stockholders’ equity	$ 1,475,406	$ 1,715,648

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Cash and cash equivalents	$ 235,393	$ 320,700
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, authorized	100,000,000	100,000,000
Preferred stock, shares issued	0	0
Preferred stock, outstanding	0	0
Common stock, authorized	1,250,000,000	1,250,000,000
Joint Venture
Cash and cash equivalents	$ 3,395	$ 3,382
Class A Common Stock
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, authorized	1,000,000,000	1,000,000,000
Common stock, issued	358,505,000	332,869,000
Common stock, outstanding	358,505,000	332,869,000
Class B Common Stock
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, authorized	250,000,000	250,000,000
Common stock, issued	79,454,000	95,450,000
Common stock, outstanding	79,454,000	95,450,000

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Income (Loss) - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Operating expenses:
Research and development	$ 297,435	$ 151,496	$ 65,103
General and administrative	123,183	63,770	15,918
Total operating expenses	420,618	215,266	81,021
Loss from operations	(420,618)	(215,266)	(81,021)
Other income (loss):
Interest expense	(2,399)	(1,419)	(20,765)
Interest income	10,905	1,883	1,093
Change in fair value of Series F convertible preferred stock tranche liabilities			(999,987)
Change in fair value of assumed common stock warrant liabilities		168,674	(581,863)
Other income	216	151	760
Total other income (loss)	8,722	169,289	(1,600,762)
Net loss	(411,896)	(45,977)	(1,681,783)
Less: Net income (loss) attributable to non-controlling interest, net of tax of $0	11	(11)	(6)
Net loss attributable to common stockholders	(411,907)	(45,966)	(1,681,777)
Net loss	(411,896)	(45,977)	(1,681,783)
Other comprehensive income (loss):
Unrealized loss on marketable securities	(13,665)	(4,177)	(121)
Total comprehensive loss	(425,561)	(50,154)	(1,681,904)
Less: Comprehensive income (loss) attributable to non-controlling interest	11	(11)	(6)
Comprehensive loss attributable to common stockholders	$ (425,572)	$ (50,143)	$ (1,681,898)
Net loss per share of common stock attributable to common stockholders
Basic	$ (0.95)	$ (0.11)	$ (6.67)
Diluted	$ (0.95)	$ (0.52)	$ (6.67)
Weighted-average shares used in computing net loss per share of common stock
Basic	432,973	404,259	252,144
Diluted	432,973	409,509	252,144

Consolidated Statements of Op_2

Consolidated Statements of Operations and Comprehensive Income (Loss) (Parenthetical) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Income Statement [Abstract]
Net income (loss) attributable to non-controlling interest, net of tax	$ 0	$ 0	$ 0

Consolidated Statements of Rede

Consolidated Statements of Redeemable Non-Controlling Interest and Stockholders' Equity - USD ($) shares in Thousands, $ in Thousands	Total	Series F Preferred Stock	Class A Common Stock	Legacy QuantumScape Series F Preferred Stock Purchase Agreement Class A Common Stock	Convertible Preferred Stock Tranche	Convertible Preferred Stock Warrants	Common Stock	Common Stock Series F Preferred Stock	Common Stock Class A Common Stock	Common Stock Legacy QuantumScape Series F Preferred Stock Purchase Agreement Class A Common Stock	Additional Paid-In Capital	Additional Paid-In Capital Series F Preferred Stock	Additional Paid-In Capital Class A Common Stock	Additional Paid-In Capital Legacy QuantumScape Series F Preferred Stock Purchase Agreement Class A Common Stock	Additional Paid-In Capital Convertible Preferred Stock Tranche	Additional Paid-In Capital Convertible Preferred Stock Warrants	Accumulated Deficit	Accumulated Other Comprehensive Income (Loss)
Beginning balance at Dec. 31, 2019	$ 148,692						$ 24				$ 444,440						$ (295,862)	$ 90
Redeemable Non-Controlling, Beginning balance at Dec. 31, 2019	1,710
Beginning balance, Shares at Dec. 31, 2019							239,777
Issuance of Series F preferred stock, net of issuance costs of $11.5 million, and settlement of associated convertible preferred stock tranche liability		$ 660,933						$ 3				$ 660,930
Issuance of stock, net of issuance costs, and settlement of associated convertible preferred stock tranche liability, Shares								28,616
Issuance of Common Stock				$ 99,800						$ 1				$ 99,799
Issuance of Common Stock, Shares										15,221
Business Combination, net of redemptions and equity issuance costs of $53.0 million	568,603						$ 8				568,595
Business Combination, net of redemptions and equity issuance costs, Shares							78,735
Reclassification of Legacy QuantumScape liabilities					$ 515,394	$ 22,625									$ 515,394	$ 22,625
Exercise of stock option	599										599
Exercise of stock option, Shares							646
Exercise of warrants, Shares							998
Stock-based compensation	17,024										17,024
Net loss	(1,681,777)																(1,681,777)
Net loss, Redeemable Non-Controlling interest	(6)
Unrealized loss on marketable securities	(121)																	(121)
Ending balance at Dec. 31, 2020	351,772						$ 36				2,329,406						(1,977,639)	(31)
Redeemable Non-Controlling, Ending balance at Dec. 31, 2020	1,704
Ending balance, Shares at Dec. 31, 2020							363,994
Redeemable Convertible Preferred Stock, Beginning balance at Dec. 31, 2020	1,704
Issuance of Common Stock			$ 462,926	$ 99,930					$ 1	$ 2			$ 462,925	$ 99,928
Issuance of Common Stock, Shares									11,960	15,221
Exercise of stock option	17,779						$ 2				17,777
Exercise of stock option, Shares							16,620
Shares issued upon vesting of restricted stock units ,shares							5,027
Exercise of warrants	672,456						$ 2				672,454
Exercise of warrants, Shares							15,497
Stock-based compensation	52,175										52,175
Net loss	(45,966)																(45,966)
Net loss, Redeemable Non-Controlling interest	(11)
Unrealized loss on marketable securities	(4,177)																	(4,177)
Ending balance at Dec. 31, 2021	1,606,895						$ 43				3,634,665						(2,023,605)	(4,208)
Redeemable Non-Controlling, Ending balance at Dec. 31, 2021	1,693
Ending balance, Shares at Dec. 31, 2021							428,319
Exercise of stock option	$ 7,555										7,555
Exercise of stock option, Shares	3,832						4,343
Shares issued upon vesting of restricted stock units ,value	$ 1,852						$ 1				1,851
Shares issued upon vesting of restricted stock units ,shares							5,297
Stock-based compensation	127,110										127,110
Net loss	(411,907)																(411,907)
Net loss, Redeemable Non-Controlling interest	11
Unrealized loss on marketable securities	(13,665)																	(13,665)
Ending balance at Dec. 31, 2022	1,317,840						$ 44				$ 3,771,181						$ (2,435,512)	$ (17,873)
Redeemable Non-Controlling, Ending balance at Dec. 31, 2022	$ 1,704
Ending balance, Shares at Dec. 31, 2022							437,959

Consolidated Statements of Re_2

Consolidated Statements of Redeemable Non-Controlling Interest and Stockholders' Equity (Parenthetical) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Redemptions and equity issuance costs		$ 53
Series F Preferred Stock
Stock issuance costs		11.5
Class A Common Stock
Stock issuance costs	$ 15.5
Legacy QuantumScape Series F Preferred Stock Purchase Agreement | Class A Common Stock
Stock issuance costs	$ 0.1	$ 0.2

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Operating activities
Net loss	$ (411,896)	$ (45,977)	$ (1,681,783)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	28,280	11,207	6,851
Amortization of right-of-use assets and non-cash lease expense	7,843	3,492	1,229
Amortization of premiums and accretion of discounts on marketable securities	3,989	11,845	1,201
Stock-based compensation expense	127,110	52,175	17,024
Change in fair value of convertible preferred stock warrant liabilities			20,765
Change in fair value of convertible preferred stock tranche liabilities			999,865
Change in fair value of assumed common stock warrant liabilities		(168,674)	581,863
Impairment of fixed assets	13,695
Other	840	899	3
Changes in operating assets and liabilities:
Prepaid expenses and other assets	5,048	(4,852)	(9,648)
Accounts payable, accrued liabilities and accrued compensation	5,611	13,178	2,447
Other long-term liabilities	2,300
Operating lease liability	(844)	(1,202)	(1,080)
Net cash used in operating activities	(218,024)	(127,909)	(61,263)
Investing activities
Purchases of property and equipment	(158,845)	(127,178)	(24,093)
Proceeds from maturities of marketable securities	837,410	894,225	99,000
Proceeds from sales of marketable securities	15,105	224,058	14,006
Purchases of marketable securities	(569,551)	(1,376,939)	(891,561)
Net cash (used in) provided by investing activities	124,119	(385,834)	(802,648)
Financing activities
Proceeds from exercise of stock options and employee stock purchase plan	9,407	17,779	599
Proceeds from exercise of warrants		151,431
Proceeds from issuance of common stock, net of issuance costs paid		462,926
Proceeds from issuance of Series F preferred stock, net of issuance costs			176,462
Proceeds from issuance of Class A Common Stock pursuant to Legacy QuantumScape Series F Preferred Stock Purchase Agreement, net of issuance costs		99,930	99,800
Business Combination, net of issuance costs paid		(1,016)	676,863
Principal payment for finance lease, net of credit	(809)	5,507
Net cash provided by financing activities	8,598	736,557	953,724
Net increase (decrease) in cash, cash equivalents and restricted cash	(85,307)	222,814	89,813
Cash, cash equivalents and restricted cash at beginning of period	338,223	115,409	25,596
Cash, cash equivalents and restricted cash at end of period	252,916	338,223	115,409
Supplemental disclosure of cash flow information
Cash paid for interest	1,610	330
Fair value of assumed common stock warrants exercised		521,025
Purchases of property and equipment, not yet paid	$ 18,192	$ 11,073	4,170
Business Combination transaction costs, accrued but not paid			1,016
Net assets assumed from Business Combination			$ 592

Cash, Cash Equivalents and Rest

Cash, Cash Equivalents and Restricted Cash by Category - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Statement of Cash Flows [Abstract]
Cash and cash equivalents	$ 235,393	$ 320,700	$ 113,216
Other assets	17,523	17,523	2,193
Total cash, cash equivalents and restricted cash	$ 252,916	$ 338,223	$ 115,409

Nature of Business

Nature of Business	12 Months Ended
	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Business	Note 1. Nature of Business Organization The original QuantumScape Corporation, now named QuantumScape Battery, Inc. (“Legacy QuantumScape”), a wholly owned subsidiary of the Company (as defined below), was founded in 2010 with the mission to revolutionize energy storage to enable a sustainable future. On November 25, 2020 (the “Closing Date”), Kensington Capital Acquisition Corp. (“Kensington”), a special purpose acquisition company, consummated the Business Combination Agreement (the “Business Combination Agreement”) dated September 2, 2020, by and among Kensington, Kensington Merger Sub Corp., a Delaware corporation and wholly owned subsidiary of Kensington (“Merger Sub”), and Legacy QuantumScape. Pursuant to the terms of the Business Combination Agreement, a business combination between Kensington and Legacy QuantumScape was effected through the merger of Merger Sub with and into Legacy QuantumScape, with Legacy QuantumScape surviving as the surviving company and as a wholly-owned subsidiary of Kensington (the “Merger” and, collectively with the other transactions described in the Business Combination Agreement, the “Business Combination”). On the Closing Date, Kensington changed its name to QuantumScape Corporation, (the “Company”). The Company is focused on the development and commercialization of its solid-state lithium-metal batteries. Planned principal operations have not yet commenced. As of December 31, 2022 , the Company had not derived revenue from its principal business activities.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Basis of Presentation The Company’s consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) as determined by the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) and pursuant to the regulations of the U.S. Securities and Exchange Commission (“SEC”). On November 25, 2020 , the Company consummated the Business Combination Agreement dated September 2, 2020 , with Legacy QuantumScape surviving the merger as a wholly owned subsidiary of the Company. At the effective time of the Merger, and subject to the terms and conditions of the Business Combination Agreement, each share of Legacy QuantumScape Class A common stock, par value $ 0.0001 per share, and each share of the Legacy QuantumScape Preferred Stock that was convertible into a share of Legacy QuantumScape Class A Common Stock, was canceled and converted into the right to receive the number of shares of the Company’s Class A Common Stock, $ 0.0001 par value per share (the “Class A Common Stock”), equal to 4.02175014920 (the “Exchange Ratio”), and each share of Legacy QuantumScape Class B Common Stock, par value $ 0.0001 per share, and each share of the Legacy QuantumScape Preferred Stock that was convertible into a share of Legacy QuantumScape Class B Common Stock was canceled and converted into the right to receive the number of shares of the Company’s Class B Common Stock, $ 0.0001 par value per share equal to the Exchange Ratio. Pursuant to the Business Combination Agreement, the merger between Merger Sub and Legacy QuantumScape was accounted for as a reverse recapitalization in accordance with U.S. GAAP (the “Reverse Recapitalization”). Under this method of accounting, Kensington was treated as the “acquired” company and Legacy QuantumScape was treated as the acquirer for financial reporting purposes. Legacy QuantumScape was determined to be the accounting acquirer based on the following predominant factors: • Legacy QuantumScape’s shareholders have the largest portion of voting rights in the Company; • the Company's Board of Directors (the “Board”) and management are primarily composed of individuals associated with Legacy QuantumScape; and • Legacy QuantumScape was the larger entity based on historical operating activity and Legacy QuantumScape has the larger employee base at the time of the Business Combination. Accordingly, for accounting purposes, the Reverse Recapitalization was treated as the equivalent of Legacy QuantumScape issuing stock for the net assets of Kensington, accompanied by a recapitalization. The net assets of Kensington were stated at historical cost, with no goodwill or other intangible assets recorded. Principles of Consolidation The Company’s policy is to consolidate all entities that it controls by ownership of a majority of the outstanding voting stock. In addition, the Company consolidates entities that meet the definition of a variable interest entity (“VIE”) for which the Company is the related party most closely associated with and is the primary beneficiary. The primary beneficiary is the party who has the power to direct the activities of a VIE that most significantly impact the entity’s economic performance and who has an obligation to absorb losses of the entity or a right to receive benefits from the entity that could potentially be significant to the entity. For consolidated entities that are less than wholly owned, the third party’s holding of an equity interest is presented as redeemable non-controlling interests in the Company’s Consolidated Balance Sheets and Consolidated Statements of Redeemable Non-Controlling Interest and Stockholders’ Equity. The portion of net earnings (loss) attributable to the redeemable non-controlling interests is presented as net income (loss) attributable to non-controlling interests in the Company’s Consolidated Statements of Operations and Comprehensive Income (Loss). The Company was a single-legal entity prior to becoming a partner with Volkswagen in QSV Operations LLC (“QSV”). As noted in the section titled “ Joint Venture and Redeemable Non-Controlling Interest ” below, the Company determined QSV was a VIE for which it was required to consolidate the operations upon its formation in 2018. The Company continued to consolidate the operations of the QSV in 2022 as the determination of the VIE has not changed. All intercompany accounts and transactions are eliminated in consolidation. Use of Estimates The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of commitments and contingencies at the date of the financial statements as well as reported amounts of expenses during the reporting periods. Estimates made by the Company include, but are not limited to, those related to the valuation of common stock prior to the Business Combination, valuation of awards under the Extraordinary Performance Award Program (the “EPA Program”), and valuation of Assumed Common Stock Warrants among others. The Company bases these estimates on historical experience and on various other assumptions that it believes are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying amounts of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates. Joint Venture and Redeemable Non-Controlling Interest QSV was incorporated as a limited liability company in 2018. Volkswagen Group of America, Inc. (“VWGoA”), Volkswagen Group of America Investments, LLC (“VGA”) and QuantumScape executed a Joint Venture Agreement (“JVA”), effective September 2018, with the goal of jointly establishing a manufacturing facility to produce the pilot line of the Company’s product through QSV. In connection with this agreement, the parties also have entered into two operating agreements: (i) the Limited Liability Company Agreement of QSV to govern the respective rights and obligations as members of QSV and (ii) the Common IP License Agreement for the Company to license certain intellectual property pertaining to automotive battery cells as defined in the JVA to VWGoA, VGA and QSV. Volkswagen is a related party stockholder (approximately 21.5 % and 19.8 % voting interest holder of the Company as of December 31, 2022 and 2021 , respectively). Upon the effectiveness of the JVA, each party contributed $ 1.7 million in cash to capitalize QSV in exchange for 50 % equity interests. The joint venture is considered a VIE with a related party and therefore the related party whose business is more closely related to the planned operations of the joint venture is required to consolidate the operations. The Company determined its operations were most closely aligned with the operations of the joint venture and therefore has consolidated the results of QSV’s operations in its Consolidated Balance Sheets, Consolidated Statements of Operations and Comprehensive Income (Loss) and Consolidated Statements of Redeemable Non-Controlling Interest and Stockholders’ Equity. QSV had minimal operations through December 31, 2022. The Company classifies non-controlling interests with redemption features that are not solely within the control of the Company within temporary equity on the Company’s Consolidated Balance Sheets in accordance with ASC 480-10-S99-3A, SEC Staff Announcement: Classification and Measurement of Redeemable Securities (“ASC 480-10-S99-3A”). The non-controlling interest was recorded outside of stockholders’ equity because the non-controlling interest provides the holder with put rights in the event of, amongst others, (i) the failure by the Company to meet specified development milestones within certain timeframes, (ii) the parties to the JVA cannot agree to certain commercial terms within certain timeframes, or (iii) a change of control of the Company, which such events are considered not solely within the Company’s control. The Company adjusts redeemable non-controlling interests for the portion of net loss attributable to the redeemable non-controlling interests. As of December 31, 2022 , the redeemable non-controlling interest is equivalent to the value of Volkswagen's interest in the joint venture. The commercialization timeline originally contemplated in 2018 by the joint venture agreements, and by subsequent amendments, has changed, and as of the time of our filing of this annual report on Form 10-K, certain milestones contemplated by the joint venture agreements were not met. As a result, Volkswagen now has the right to exercise its put rights. If Volkswagen exercises such rights, the joint venture with Volkswagen and Volkswagen’s commitments to purchase output capacity from the joint venture would terminate, and we would be obligated to purchase Volkswagen’s interest in the joint venture for its book value. As of December 31, 2022, the book value of this interest was approximately $ 1.7 million and is recorded as a redeemable non-controlling interest in our Consolidated Balance Sheets. To date, Volkswagen has not informed us of any intention to exercise their put rights. Concentrations of Credit Risk Financial instruments that potentially subject the Company to credit risk consist principally of cash and cash equivalents and marketable securities. As of December 31, 2022 and 2021 , approximately $ 107.4 million and $ 227.8 million of our total cash and cash equivalents and marketable securities, are held in U.S. money market funds, and $ 610.5 million and $ 722.3 million are invested in U.S. government and agency securities, respectively. The Company seeks to mitigate its credit risk with respect to cash and cash equivalents and marketable securities by making deposits with large, reputable financial institutions and investing in high credit rated shorter-term instruments. Cash and Cash Equivalents and Restricted Cash Management considers all highly liquid investments with original maturities of three months or less to be cash equivalents. Restricted cash is maintained under an agreement that legally restricts the use of such funds and is reported within other assets as the date of availability or disbursement for all restricted cash is more than one year from December 31, 2022. Restricted cash is comprised of $ 17.5 million, as of both December 31, 2022 and December 31, 2021 , all of which is pledged as a form of security for the Company’s lease agreements for its headquarters and pre-pilot manufacturing facilities. Marketable Securities The Company’s investment policy is consistent with the definition of available-for-sale securities. The Company does not buy and hold securities principally for the purpose of selling them in the near future. The Company’s policy is focused on the preservation of capital, liquidity, and return. From time to time, the Company may sell certain securities, but the objectives are generally not to generate profits on short-term differences in price. These securities are carried at estimated fair value with unrealized gains and losses included in other comprehensive gain/loss in stockholders’ equity until realized. Gains and losses on marketable security transactions are reported on the specific-identification method. Dividend and interest income are recognized when earned. Fair Value Measurement The Company applies fair value accounting for all financial assets and liabilities measured on a recurring and nonrecurring basis. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. The accounting guidance established a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, used to determine the fair value of its financial instruments. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. • Level 1 – Quoted prices in active markets for identical assets or liabilities that the entity has the ability to access. • Level 2 – Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets and liabilities. • Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets and liabilities. Property and Equipment Property and equipment are recorded at historical cost, less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful life of the related asset. Improvements that increase functionality of the fixed asset are capitalized and depreciated over the asset’s remaining useful life. Deposits for purchases of property and equipment are included in construction-in-progress. Construction-in-progress is not depreciated until the asset is placed in service. Fully depreciated assets are retained in property and equipment, net, until removed from service. The estimated useful lives of assets are generally as follows: Computer equipment, hardware, and software 3 - 5 years Furniture and fixtures 7 - 10 years Machinery and equipment 3 - 10 years Leasehold improvements Shorter of the lease term (including estimated renewals) or the estimated useful lives of the improvements Impairment of Long-Lived Assets The Company evaluates the carrying value of long-lived assets when indicators of impairment exist. The carrying value of a long-lived asset is considered impaired when the estimated separately identifiable, undiscounted cash flows from such an asset are less than the carrying value of the asset. In that event, a loss is recognized based on the amount by which the carrying value exceeds the fair value of the long-lived asset. Fair value is determined primarily using the estimated cash flows discounted at a rate commensurate with the risk involved. The long-lived assets outside of U.S. are not material as of December 31, 2022. There was no material impairment charge in the year ended December 31, 2021, or December 31, 2020. During the year ended December 31, 2022, the Company wrote off approximately $ 13.7 million of equipment and incurred cancellation charges of approximately $ 2.8 million to focus on process and equipment development designed to deliver higher throughput with fewer processing steps. These charges are recorded in Research and Development expense in the Consolidated Statements of Operations and Comprehensive Income (Loss). Leases The Company classifies arrangements meeting the definition of a lease as operating or financing leases, and leases are recorded on the Consolidated Balance Sheets as both a right-of-use (“ROU”) asset and lease liability, calculated by discounting fixed lease payments over the lease term at the rate implicit in the lease or the Company’s incremental borrowing rate which is the rate incurred to borrow on a collateralized basis over a similar term. Lease liabilities are increased by interest and reduced by payments each period, and the ROU asset is reduced over the lease term. For operating leases, interest on the lease liability and the non-cash lease expense result in straight-line rent expense over the lease term. For finance leases, interest on the lease liability and the amortization of the ROU asset results in front-loaded expense over the lease term. Variable lease expenses, including common maintenance fees, insurance and property tax, are recorded when incurred. In calculating the right-of-use asset and lease liability, the Company elects to combine lease and non-lease components for all classes of assets, and elects to exclude short-term leases having terms of 12 months or less. Assumed Common Stock Warrants Liability The Company assumed 11,499,989 Public Warrants and 6,650,000 Private Placement Warrants upon the Business Combination, all of which were issued in connection with Kensington’s initial public offering (other than 75,000 Private Placement Warrants that were issued in connection with the closing of the Business Combination, which are referred to as the Working Capital Warrants) and entitled each holder to purchase one share of Class A Common Stock at an exercise price of $ 11.50 per share. The Company evaluated the Assumed Common Stock Warrants under ASC 815-40, Derivatives and Hedging—Contracts in Entity’s Own Equity ( “ ASC 815-40 ” ) , and concluded they did not meet the criteria to be classified in stockholders’ equity. Specifically, the exercise of the Assumed Common Stock Warrants could have been settled in cash upon the occurrence of a tender offer or exchange that involves 50 % or more of our holders of Class A Common Stock. Because not all of the voting stockholders need to participate in such tender offer or exchange to trigger the potential cash settlement and the Company does not control the occurrence of such an event, the Company concluded that the Assumed Common Stock Warrants did not meet the conditions to be classified in equity. Since the Assumed Common Stock Warrants meet the definition of a derivative under ASC 815, the Company recorded these warrants as liabilities on the Consolidated Balance Sheets at fair value, with subsequent changes in their respective fair values recognized in the change in fair value of Assumed Common Stock Warrant liabilities within the Consolidated Statement of Operations and Comprehensive Income (Loss) at each reporting date prior to exercise or redemption. As described in Note 7, Commitments and Contingencies, below, the Company announced that it had elected to redeem its outstanding Public Warrants and Private Placement Warrants in July and August 2021, respectively. As of December 31, 2021, no Public Warrants or Private Placement Warrants were outstanding. As of December 31, 2020, 11,499,989 Public Warrants and 6,650,000 Private Placement Warrants were outstanding. Segments Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the Chief Operating Decision Maker (“CODM”) in deciding how to allocate resources to an individual segment and in assessing performance. The Company’s CODM is its Chief Executive Officer. The Company has determined that it operates in one operating segment and one reportable segment, as the CODM reviews financial information presented on a consolidated basis for purposes of making operating decisions, allocating resources, and evaluating financial performance. Research and Development Cost Costs related to research and development are expensed as incurred. General and Administrative Expenses General and administrative expenses represent costs incurred by the Company in managing the business, including salary, benefits, incentive compensation, marketing, insurance, professional fees and other operating costs associated with the Company’s non-research and development activities. Stock-Based Compensation The Company measures and recognizes compensation expense for all stock-based awards made to employees, directors, and non-employees, including stock options, restricted share units and restricted shares, based on estimated fair values recognized over the requisite service period. The fair values of options granted with only service conditions are estimated on the grant date using the Black-Scholes option pricing model. This valuation model for stock-based compensation expense requires the Company to make assumptions and judgments about the variables used in the calculation, including the expected term (weighted-average period of time that the options granted are expected to be outstanding), the volatility of the Company’s common stock, and an assumed risk-free interest rate. The Company accounts for forfeitures when they occur. The fair values of options granted with performance (e.g., business milestone) and market conditions (e.g., stock price target) are estimated at the grant date using a Monte Carlo simulation model. The model determined the grant date fair value of each vesting tranche and the future date when the market condition for such tranche is expected to be achieved. The Monte Carlo valuation requires the Company to make assumptions and judgements about the variables used in the calculation including the expected term, volatility of the Company's common stock, an assumed risk-free interest rate, and cost of equity. For performance-based awards with a vesting schedule based entirely on the attainment of both performance and market conditions, each quarter the Company assesses whether it is probable that it will achieve each performance condition that has not previously been achieved or deemed probable of achievement and if so, the future time when the Company expects to achieve that business milestone, or its “expected business milestone achievement time.” When the Company first determines that a business milestone has become probable of being achieved, the Company allocates the entire expense for the related tranche over the number of quarters between the grant date and the then-applicable “expected vesting date,” which represents the requisite service period. The requisite service period at any given time is generally the period between the grant date and the later of (i) the expected time when the performance condition will be achieved (if the related performance condition has not yet been achieved) and (ii) the expected time when the market condition will be achieved (if the related market condition has not yet been achieved). The Company immediately recognizes a cumulative catch-up expense for all accumulated expense for the quarters from the grant date through the quarter in which the performance condition was first deemed probable of being achieved. Each quarter thereafter, the Company recognizes the then-remaining expense for the tranche through the end of the requisite service period except that upon vesting of a tranche, all remaining expense for that tranche is immediately recognized. The Company accounts for forfeitures when they occur. The Company estimates the fair value of restricted stock units based on the closing price of the Company’s Class A Common Stock on the date of grant. The Company’s 2020 Employee Stock Purchase Plan (“ESPP”) is compensatory in accordance with ASC 718-50-25. The Company measures and recognizes compensation expense for shares to be issued under the ESPP based on estimated grant date fair value recognized on a straight-line basis over the offering period. The first offering period for the ESPP commenced in June 2021. The ESPP provides eligible employees with the opportunity to purchase shares of the Company’s Class A Common Stock at a discount through payroll deductions. A participant may purchase a maximum of 1,000 shares of Class A Common Stock during each six-month offering period. As of December 31, 2022 , 11.3 million shares of Class A Common Stock were reserved for future issuance under the ESPP. There were 510,993 shares purchased under the ESPP during the year ended December 31, 2022 . Income Taxes The Company accounts for income taxes under an asset and liability approach. Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes and operating loss carryforwards, measured by applying currently enacted tax laws. Valuation allowances are provided when necessary to reduce net deferred tax assets to an amount that is more likely than not to be realized. The Company recognizes tax liabilities based upon its estimate of whether, and the extent to which, additional taxes will be due when such estimates are more likely than not to be sustained. An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained. Net Loss per Share of Common Stock Basic net income (loss) per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted earnings (loss) per share adjusts basic earnings per share for the potentially dilutive impact of stock options and warrants. For warrants that are liability-classified, during periods when the impact is dilutive, the Company assumes share settlement of the instruments as of the beginning of the reporting period and adjusts the numerator to remove the change in fair value of the warrant liability and adjusts the denominator to include the dilutive shares calculated using the treasury stock method.

Recent Accounting Pronouncement

Recent Accounting Pronouncements	12 Months Ended
	Dec. 31, 2022
Accounting Standards Update and Change in Accounting Principle [Abstract]
Recent Accounting Pronouncements	3. Recent Accounting Pronouncements In August 2020, the FASB issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, which simplifies accounting for convertible instruments by removing major separation models required under current U.S. GAAP. The ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception and it also simplifies the diluted earnings per share calculation in certain areas. The ASU is effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than for fiscal years beginning after December 15, 2021, and adoption must be as of the beginning of the Company’s annual fiscal year. The Company adopted this guidance in the first quarter of fiscal 2022. The adoption of such guidance had no impact on the Company’s consolidated financial statements as the Company does not have any convertible instruments as of December 31, 2022 . In November 2021, the FASB issued ASU 2021-10, Government Assistance (Topic 832), Disclosures by Business Entities About Government Assistance , which requires entities to provide disclosures on material government transactions for annual reporting periods. The disclosures include information around the nature of the assistance, the related accounting policies used to account for government assistance, the effect of government assistance on the entity’s financial statements, and any significant terms and conditions of the agreements, including commitments and contingencies. The ASU is effective for financial statements issued for annual periods beginning after December 15, 2021, with early adoption permitted. The Company adopted this guidance in the first quarter of fiscal 2022. The adoption of such guidance had no material impact on the Company’s consolidated financial statements as of December 31, 2022 . In December 2022, the FASB issued ASU 2022-06, Reference Rate Reform (Topic 848), Deferral of the Sunset Date of Topic 848 , which defers the sunset date of Topic 848 from December 31, 2022 to December 31, 2024, after which entities will no longer be permitted to apply the relief in Topic 848 that provides optional guidance to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting. The ASU is effective for all entities upon issuance. The Company adopted the guidance in December 2022. The adoption of such guidance had no impact on the Company's consolidated financial statements as of December 31, 2022 .

Fair Value Measurement

Fair Value Measurement	12 Months Ended
	Dec. 31, 2022
Fair Value Disclosures [Abstract]
Fair Value Measurement	Note 4. Fair Value Measurement The Company’s financial assets and liabilities subject to fair value measurements on a recurring basis and the level of inputs used for such measurements were as follows (amounts in thousands): Fair Value Measured as of December 31, 2022 Level 1 Level 2 Total Assets included in: Money market funds (1) $ 107,439 $ — $ 107,439 Commercial paper (2) — 104,231 104,231 U.S. government and agency securities (2) — 610,450 610,450 Corporate notes and bonds (2) — 188,658 188,658 Total fair value $ 107,439 $ 903,339 $ 1,010,778 Fair Value Measured as of December 31, 2021 Level 1 Level 2 Total Assets included in: Money market funds (1) $ 227,826 $ — $ 227,826 Commercial paper (2) — 233,400 233,400 U.S. government securities (2) — 722,310 722,310 Corporate notes and bonds (2) — 257,384 257,384 Total fair value $ 227,826 $ 1,213,094 $ 1,440,920 (1) Money market funds are included in cash and cash equivalents on the Consolidated Balance Sheets. (2) Marketable securities consist of commercial paper, U.S. government and agency securities, corporate notes and bonds. As of December 31, 2022 and 2021 , marketable securities with original maturities of three months or less of $ 77.0 million and $ 86.1 million, respectively, are included in cash and cash equivalents on the Consolidated Balance Sheets. Level 1 assets and liabilities: Money market funds are classified as Level 1 within the fair value hierarchy, as fair value is based on unadjusted quoted prices in active markets for identical assets and liabilities. Level 2 assets and liabilities: Investments in government securities, corporate bonds and commercial paper are classified as Level 2 as they were valued based upon quoted market prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant inputs are observable in the market or can be corroborated by observable market data for substantially the full term of the assets. The Company had no financial liabilities subject to fair value measurements on a recurring basis as of December 31, 2022 and December 31, 2021. There have been no changes to the valuation methods utilized during the year ended December 31, 2022. As of December 31, 2022 and 2021, the carrying values of cash and cash equivalents, accounts payable and accrued liabilities approximate their respective fair values due to their short-term nature. Marketable Securities The following table summarizes, by major security type, the Company’s assets that are measured at fair value on a recurring basis and are categorized using the fair value hierarchy. Amortized cost net of unrealized gain (loss) is equal to fair value as of December 31, 2022 and 2021 . The fair value as of December 31, 2022 and 2021, are as follows (amounts in thousands): December 31, 2022 Amortized Cost Gross Gross Fair Value Level 1 securities Money market funds $ 107,439 $ — $ — $ 107,439 Level 2 securities Commercial paper 104,231 — — 104,231 U.S. government and agency securities 620,660 24 ( 10,234 ) 610,450 Corporate notes and bonds 196,321 — ( 7,663 ) 188,658 Total $ 1,028,651 $ 24 $ ( 17,897 ) $ 1,010,778 December 31, 2021 Amortized Cost Gross Gross Fair Value Level 1 securities Money market funds $ 227,826 $ — $ — $ 227,826 Level 2 securities Commercial paper 233,400 — — 233,400 U.S. government securities 724,554 — ( 2,244 ) 722,310 Corporate notes and bonds 259,348 — ( 1,964 ) 257,384 Total $ 1,445,128 $ — $ ( 4,208 ) $ 1,440,920 Any realized gains and losses and interest income are included in interest income. The Company regularly reviews its available-for-sale marketable securities in an unrealized loss position and evaluate the current expected credit loss by considering factors such as historical experience, market data, issuer-specific factors, and current economic conditions. The following tables display additional information regarding gross unrealized losses and fair value by major security type for the 95 and 118 marketable securities in unrealized loss position as of December 31, 2022 and 2021, respectively (amounts in thousands): December 31, 2022 Less than 12 Consecutive Months 12 Consecutive Months or Longer Total Gross Fair Value Gross Fair Value Gross Fair Value U.S. government and agency securities $ ( 521 ) $ 231,047 $ ( 9,713 ) $ 336,517 $ ( 10,234 ) $ 567,564 Corporate notes and bonds ( 261 ) 18,585 ( 7,402 ) 170,073 ( 7,663 ) 188,658 Total $ ( 782 ) $ 249,632 $ ( 17,115 ) $ 506,590 $ ( 17,897 ) $ 756,222 December 31, 2021 Less than 12 Consecutive Months 12 Consecutive Months or Longer Total Gross Fair Value Gross Fair Value Gross Fair Value U.S. government securities $ ( 2,239 ) $ 700,318 $ ( 5 ) $ 17,011 $ ( 2,244 ) $ 717,329 Corporate notes and bonds ( 1,964 ) 257,384 — — ( 1,964 ) 257,384 Total $ ( 4,203 ) $ 957,702 $ ( 5 ) $ 17,011 $ ( 4,208 ) $ 974,713 The unrealized losses were attributable to changes in interest rates that impacted the value of the investments, and not increased credit risk. During the years ended December 31, 2022, 2021, and 2020 , the Company received proceeds of $ 15.2 million, $ 225.1 million, and $ 14.0 million, including interest, from the sale of available-for-sale marketable securities, respectively. The Company realized immaterial gains and losses as a result of such sales. The Company does not intend to sell the investments that are in an unrealized loss position, nor is it more likely than not that the Company will be required to sell the investments before the recovery of the amortized cost basis, which may be its maturity. Accordingly, the Company did no t record an allowance for credit losses associated with these investments. The estimated amortized cost and fair value of available-for-sale securities by contractual maturity as of December 31, 2022, are as follows (amounts in thousands): December 31, 2022 Amortized Cost Fair Value Due within one year $ 803,011 $ 797,053 Due after one year and through five years 225,640 213,725 Total $ 1,028,651 $ 1,010,778 Convertible Preferred Stock Tranche Liabilities In May 2020 and September 2020, Legacy QuantumScape executed a stock purchase agreement and related agreements and amendments thereto, with VGA for an investment of $ 200 million in Legacy QuantumScape’s Series F convertible preferred stock. The terms of the Series F Preferred Stock Purchase Agreement with VGA obligated Legacy QuantumScape to issue and sell, and VGA to purchase, up to a total of 7,569,508 shares of Series F convertible preferred stock (the “tranche shares”) at $ 26.4218 per share, to be funded in two tranches: (1) 3,784,754 shares of Legacy QuantumScape Series F Preferred Stock issued for $ 100 million on December 1, 2020 (the time-based portion of the agreement, “tranche shares 1”), and (2) 3,784,754 shares of Legacy QuantumScape Series F Preferred Stock will be issued for $ 100 million subject to certain conditions including the achievement of a specified technical milestone by March 31, 2021, as set forth in such agreements (“tranche shares 2”). The Company concluded that the firm commitment to issue the tranche shares met the definition of a freestanding financial instrument. As the underlying convertible preferred shares of the outstanding tranche liabilities were redeemable outside the control of the Company, the fair value of the tranche liabilities was reported on the Company’s balance sheets as a long-term liability, and the fair value change was recorded in other expense in the Consolidated Statements of Operations and Comprehensive Loss, as noted in the table below. The Series F Preferred Stock Purchase Agreement with VGA, as amended, contains provisions pursuant to which, if the relevant closing of such Series F Preferred Stock Purchase Agreement (in whole or in part) occur only after effectiveness of the Merger, VGA agreed to purchase, and the Company agreed to issue, instead of the relevant number of shares of Legacy QuantumScape Series F Preferred Stock to be purchased at such closing, such number of shares of Class A Common Stock as would have been issued in the Merger in exchange for such shares of Legacy QuantumScape Series F Preferred Stock if they had been outstanding prior to the Merger. As a result of these provisions to issue shares of Class A Common Stock, and upon consummation of the Business Combination, the Company determine its obligation to issue Class A Common Stock pursuant to the Series F Preferred Stock Purchase Agreement was equity classified and the fair value of the tranche liabilities was reclassified to additional paid-in capital. In August 2020, Legacy QuantumScape entered into Series F Preferred Stock Purchase Agreements and related agreements thereto with several new and existing investors, pursuant to which it agreed to sell, and the investors agreed to purchase, an aggregate of 7,115,335 shares of Legacy QuantumScape Series F Preferred Stock at $ 26.4218 per share for an aggregate purchase price of $ 188 million (tranche shares 3 and 4), of which: (1) $ 94.0 million was to be funded at the earlier of December 1, 2020 or a SPAC business combination (“tranche shares 3”), and (2) the remaining $ 94.0 million tranche (“tranche shares 4”) was to be funded at the earlier of a SPAC business combination closing or March 2021. Similar to the tranche shares to VGA, the Company concluded that the firm commitment to issue the incremental tranche shares 3 and 4 met the definition of a freestanding financial instrument. Pursuant to the terms of these Series F Preferred Stock Purchase Agreements, funding of the tranche shares 3 and 4 occurred concurrent with the closing of the Business Combination. Upon funding and issuance of the 7,115,335 shares of Legacy QuantumScape Series F Preferred Stock, the convertible preferred stock tranche liability associated with tranche shares 3 and 4 was settled and the fair value of the tranche liability was recorded as redeemable convertible preferred stock. The Company remeasured all tranche share liabilities as of closing date of the Business Combination based on the closing market price of Kensington immediately prior to the Business Combination. The fair value of the Series F convertible preferred stock tranche liabilities was calculated based on the traded stock price of Kensington at November 25, 2020 of $ 23.50 , adjusted for the Exchange Ratio, less the Series F exercise price of $ 26.42 . The following table presents the reconciliation of the Series F convertible preferred tranche liabilities measured and recorded at fair value on a recurring basis using the significant unobservable inputs described above (amounts in thousands): Fair Value Balance as of December 31, 2019 $ — Issuance and re-measurement loss recorded in other expense 999,865 Issuance of Legacy QuantumScape Series F Preferred Stock - tranche shares 3 and 4 ( 484,471 ) Reclassification to additional paid-in capital upon Closing of the Business Combination - tranche shares 1 and 2 ( 515,394 ) Balance as of December 31, 2020 $ —

Balance Sheet Components

Balance Sheet Components	12 Months Ended
	Dec. 31, 2022
Balance Sheet Related Disclosures [Abstract]
Balance Sheet Components	Note 5. Balance Sheet Components Property and Equipment Property and equipment as of December 31, 2022 and 2021, consisted of the following (amounts in thousands): December 31, 2022 2021 Computer equipment, hardware, and software $ 6,784 $ 2,740 Furniture and fixtures 57,771 15,116 Leasehold improvements 72,201 23,192 Machinery and equipment 120,618 66,953 Construction-in-progress 108,585 101,420 Property and equipment, gross 365,959 209,421 Accumulated depreciation and amortization ( 70,025 ) ( 43,238 ) Property and equipment, net $ 295,934 $ 166,183 Depreciation and amortization expense related to property and equipment was $ 27.4 million, $ 11.7 million and $ 7.5 million for the years ended December 31, 2022, 2021 and 2020, respectively. Accrued Liabilities Accrued liabilities as of December 31, 2022 and 2021, consisted of the following (amounts in thousands): December 31, 2022 2021 Accrued property and equipment $ 3,152 $ 1,815 Accrued facilities expense 1,106 1,637 Other 3,219 2,626 Accrued liabilities $ 7,477 $ 6,078 Other Liabilities Other liabilities as of December 31, 2022 and 2021, consisted of the following (amounts in thousands): December 31, 2022 2021 Long-term advance payments $ 2,615 $ 315 Asset retirement obligation 5,873 — Other liabilities $ 8,488 $ 315

Leases

Leases	12 Months Ended
	Dec. 31, 2022
Leases [Abstract]
Leases	Note 6. Leases The Company leases its headquarters, pre-pilot manufacturing facilities and certain equipment, with current lease terms running through 2032 . Fixed rent generally escalates each year, and the Company is responsible for a portion of the landlords’ operating expenses such as property tax, insurance and common area maintenance. In April 2021, the Company entered into a lease agreement for premises consisting of approximately 197,000 rentable square feet of space located in San Jose, California to be used for QS-0. The lease expires in September 2032 . Under this QS-0 lease, the Company has two five-year renewal options, which have not been included in the calculation of the lease liability and right-of use asset at the lease inception as the exercise of the options was not reasonably certain. This initial QS-0 lease is classified as a finance lease. In June 2021, the Company amended the terms of its 2013 headquarter lease to provide for, among other things, an extension of the lease term to September 2032 . Under the amended headquarter lease, the Company retained its one five-year renewal option, which has not been included in the calculation of lease liabilities and right of use assets at the amendment date, as the exercise of the option was not reasonably certain. In November 2021, the Company entered into lease agreements for additional premises consisting of approximately 222,000 rentable square feet of space in San Jose, California adjacent to the site of QS-0. The November 2021 leases represent an expansion of space for QS-0 and the Company’s engineering and development activities. Such leases will expire in September 2032 but include an option to extend the terms of the lease for an additional 10-year period. The November 2021 leases commenced in November 2021, January 2022, and April 2022 and were classified as operating leases. The additional 10-year extension period has not been included in the calculation of the lease liability and right-of-use asset at the lease inception as the exercise of the option was not reasonably certain. The Company’s leases do not have any contingent rent payments and do not contain residual value guarantees. The components of lease-related expense are as follows (amounts in thousands): Year Ended December 31, Lease costs 2022 2021 2020 Finance lease costs: Amortization of right-of-use assets $ 2,873 $ 1,915 $ — Interest on lease liabilities 2,399 1,419 — Operating lease costs 9,082 3,016 2,143 Variable lease costs 2,330 530 409 Total lease expense $ 16,684 $ 6,880 $ 2,552 The components of supplemental cash and noncash information related to leases are as follows (amounts in thousands): Year Ended December 31, 2022 2021 2020 Operating outgoing cash flows - finance lease $ 1,610 $ 330 $ — Financing outgoing cash flows - finance lease 809 73 — Financing (incoming) cash flows - finance lease — ( 5,580 ) — Operating outgoing cash flows - operating lease 4,673 2,711 1,994 Right-of-use assets obtained in exchange for new finance lease liabilities — 32,802 — Right-of-use assets obtained in exchange for new operating lease liabilities 28,845 26,778 — The table below displays additional information for leases: December 31, 2022 2021 Finance lease Weighted-average remaining lease term - finance lease (in years) 9.8 10.8 Weighted-average discount rate - finance lease 6.06 % 6.06 % Operating lease Weighted-average remaining lease term - operating lease (in years) 9.6 10.7 Weighted-average discount rate - operating lease 6.36 % 6.34 % As of December 31, 2022, future minimum payments during the next five years and thereafter are as follows (amounts in thousands): Fiscal Year Operating Finance 2023 $ 7,461 $ 3,751 2024 8,892 5,131 2025 9,104 5,272 2026 9,039 5,417 2027 9,135 5,565 Thereafter 46,370 28,065 Total 90,001 53,201 Less present value discount ( 23,963 ) ( 13,823 ) Lease liabilities $ 66,038 $ 39,378 As the Company’s lease agreements do not provide an implicit rate, the Company used an estimated incremental borrowing rate that will be incurred to borrow on a collateralized basis over a similar term at the lease commencement date or modification date in determining the present value of lease payments. Asset Retirement Obligations The Company establishes asset s and liabilities for the present value of estimated future costs to return certain of our leased facilities to their original condition upon the termination or expiration of a lease. The recognition of an asset retirement obligation requires the Company to make assumptions and judgments including the actions required to satisfy the liability, inflation rates and the credit-adjusted risk-free rate. The initially recognized asset retirement cost is amortized using the same method and useful life as the long-lived asset to which it relates. Accretion expense is recognized over time as the discounted liability is accreted to its expected settlement value.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 7. Commitments an d Contingencies From time to time, and in the ordinary course of business, the Company may be subject to certain claims, charges and litigation concerning matters arising in connection with the conduct of the Company’s business activities. Warrants Litigation Purported Company warrantholders filed actions against the Company in the United States District Court for the Southern District of New York alleging, among other things, that they were entitled to exercise their warrants within 30 days of the closing of the Business Combination and that the preliminary and final versions of the proxy statement/prospectus/information statement dated September 21, 2020, and November 12, 2020, were misleading and/or omitted material information concerning the exercise of the warrants. The actions have been consolidated for the purposes of discovery and motion practice. The operative consolidated complaint, filed January 21, 2022, seeks monetary damages for alleged breach of contract, securities law violations, and fraud. The parties have moved for partial summary judgment, which motions are pending. QuantumScape continues to believe it has meritorious defenses to the claims and intends to defend itself vigorously. Securities Class Action Litigation Beginning in January 2021 class action lawsuits were filed in the United States District Court for the Northern District of California by purported purchasers of Company securities. Lead plaintiff filed a consolidated complaint on June 21, 2021, which alleges a purported class that includes all persons who purchased or acquired our securities between November 27, 2020 and April 14, 2021. The consolidated complaint names the Company, its Chief Executive Officer, its Chief Financial Officer, and its Chief Technology Officer as defendants. The consolidated complaint alleges that the defendants purportedly made false and/or misleading statements and failed to disclose material adverse facts about the Company’s business, operations, and prospects, including information regarding the Company’s battery technology. On January 14, 2022, defendants’ motion to dismiss the consolidated complaint was substantially denied. On December 19, 2022, the court granted plaintiffs’ motion to certify the class. Defendants filed a petition with the Ninth Circuit Court of Appeals seeking permission to appeal the certification order. QuantumScape continues to believe it has meritorious defenses to the claims and intends to defend itself vigorously. Shareholder Derivative Litigation Two shareholder derivative suits were filed in February 2021 in the United States District Court for the Northern District of California against 11 officers and directors of the Company and have been consolidated into one action, with the first-filed complaint being designated the operat ive one. The Company is the nominal defendant. The complaint alleges that the individual defendants breached various duties to the Company and contains additional similar allegations based on the same general allegations in the class action described immediately above. VGA is also named as a defendant in the derivative litigation. The action is currently stayed. Four shareholder deriv ative suits were filed beginning in June 2022 in the Court of Chancery of the State of Delaware against current and former directors and officers of the Company. The Company is the nominal defendant. The complaints allege that the individual defendants breached various duties to the Company. VGA is also named as a defendant in two of those actions. The suits were consolidated and are currently stayed. Another shareholder derivative suit was filed in the Court of Chancery of the State of Delaware on August 16, 2022, against former and current directors and officers of the Company and of Kensington. The Company is the nominal defendant. The complaint alleges that the individual defendants breached various duties to the Company. Defendants moved to dismiss the complaint, which motion is pending. Section 205 Proceeding On February 9, 2023, the Company filed a petition in the Court of Chancery of the State of Delaware pursuant to Section 205 of the DGCL asking the Court to ratify and validate potentially defective corporate acts (the “Petition”). The Petition concerned a November 25, 2020 vote by the stockholders of the Company to approve certain matters relating to the Business Combination. Among these matters was a proposal to amend the Company's then-effective Amended and Restated Certificate of Incorporation to, among other things, (i) increase the total number of authorized shares of Class A common stock, and (ii) opt out of the separate class voting requirements of Section 242(b)(2) of the DGCL (collectively the “Charter Amendments”). The Charter Amendments were approved by a majority of the shares of the Company's Class A common stock and Class B common stock, voting as a single class. A recent ruling by the Court of Chancery introduced uncertainty as to whether Section 242(b)(2) of the DGCL would have required the Charter Amendments to be approved by a separate vote of the majority of the Company's then-outstanding shares of Class A common stock. In light of that ruling, the Petition sought validation of the filing and effectiveness of the Charter Amendments and the shares and securities issued in reliance on the Charter Amendments to resolve any uncertainty with respect to those matters. A hearing on the merits of the Petition was held on February 27, 2023. The Court granted the relief sought in the Petition, validating and declaring effective pursuant to Section 205 of the DGCL the filing and effectiveness of the Charter Amendments and the shares and securities issued in reliance on the Charter Amendments. For many legal matters, particularly those in early stages, the Company cannot reasonably estimate the possible loss (or range of loss), if any. The Company records an accrual for legal matters at the time or times it determines that a loss is both probable and reasonably estimable. Amounts accrued as of December 31, 2022 and 2021 were not material. Regarding matters for which no accrual has been made (including the potential for losses in excess of amounts accrued), the Company currently believes, based on its own investigations, that any losses (or ranges of losses) that are reasonably possible and estimable will not, in the aggregate, have a material adverse effect on its financial position, results of operations, or cash flows. However, the ultimate outcome of legal proceedings involves judgments, estimates, and inherent uncertainties and cannot be predicted with certainty. Should the ultimate outcome of any legal matter be unfavorable, the Company's business, financial condition, results of operations, or cash flows could be materially and adversely affected. The Company may also incur substantial legal fees, which are expensed as incurred, in defending against legal claims. Other commitments The Company's minimum purcha se commitments consist of non-cancellable agreements to purchase goods and services, primarily for materials, and licenses and hosting services, entered into in the ordinary course of business. As of December 31, 2022, future minimum purchase commitments in aggregate during the next five years and thereafter are as follows (amounts in thousands): Fiscal Year Minimum Purchase Commitments 2023 $ 2,775 2024 3,150 2025 2,358 2026 2,105 2027 1,418 Thereafter — Total $ 11,806

Assumed Common Stock Warrants

Assumed Common Stock Warrants	12 Months Ended
	Dec. 31, 2022
Warrants and Rights Note Disclosure [Abstract]
Assumed Common Stock Warrants	Note 8. Assumed Common Stock Warrants The Company assumed 11,499,989 Public Warrants and 6,650,000 Private Placement Warrants upon the Business Combination, all of which were issued in connection with Kensington’s initial public offering (other than 75,000 Private Placement Warrants that were issued in connection with the closing of the Business Combination, which are referred to as the Working Capital Warrants) and entitled each holder to purchase one share of Class A Common Stock at an exercise price of $ 11.50 per share. The Company recorded these warrants as liabilities on the Consolidated Balance Sheets at fair value, with subsequent changes in their respective fair values recognized in the Change in fair value of Assumed Common Stock Warrant liabilities within the Consolidated Statement of Operations and Comprehensive Income (Loss) at each reporting date prior to exercise or redemption. The Public Warrants were publicly traded and thus had an observable market price to estimate fair value, and the Private Placement Warrants were effectively valued similar to the Public Warrants. As a result, the Company recognized a $ 168.7 million gain and $ 581.9 million loss non-cash change in fair value of Assumed Common Stock Warrant liabilities, in the Consolidated Statements of Operations and Comprehensive Income (Loss) for the years ended December 31, 2021 and 2020, respectively. All Public Warrants and Private Placement Warrants were exercised or redeemed during the year ended December 31, 2021.

Stockholders' Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2022
Stockholders' Equity Note [Abstract]
Stockholders' Equity	Note 9. Stockholders’ Equity As of December 31, 2022 and 2021 , 1,350,000,000 shares, $ 0.0001 par value per share are authorized, of which, 1,000,000,000 shares are designated as Class A Common Stock, 250,000,000 shares are designated as Class B Common Stock, and 100,000,000 shares are designated as Preferred Stock. Common Stock Holders of the common stock are entitled to dividends when, as, and if, declared by the Board, subject to the rights of the holders of all classes of stock outstanding having priority rights to dividends. As of December 31, 2022 , the Company had not declared any dividends. The holder of each share of Class A Common Stock is entitled to one vote, and the holder of each share of Class B Common Stock is entitled to ten votes. In March 2021, the Company completed an underwritten public offering of shares of its Class A Common Stock and issued 11,960,000 shares for an aggregate purchase price of $ 462.9 million, net of issuance costs of $ 15.5 million (the “March 2021 Public Offering”). Equity Incentive Plans Prior to the Business Combination, the Company maintained its 2010 Equity Incentive Plan (the “2010 Plan”), under which the Company granted options and restricted share units to purchase or directly issue shares of common stock to employees, directors, and non-employees. Upon the closing of the Business Combination, awards under the 2010 Plan were converted at the Exchange Ratio and assumed into the 2020 Equity Incentive Award Plan (the “2020 Plan”, and together with the 2010 Plan, the “Plans”). The 2020 Plan permits the granting of awards in the form of incentive stock options, nonqualified stock options, stock appreciation rights, restricted shares, restricted share units and performance awards to employees, directors, and non-employees. As of December 31, 2022 , 62,915,959 shares of Class A Common Stock are authorized for issuance pursuant to awards under the 2020 Plan, plus any shares of Class A Common Stock subject to stock options, restricted stock units or other awards that were assumed in the Business Combination and terminate as a result of being unexercised or are forfeited or repurchased by the Company, with the maximum number of shares to be added to the 2020 Plan equal to 69,846,580 shares of Class A Common Stock. As of December 31, 2022 , 33,806,148 shares of Class A Common Stock are reserved and available for future issuance under the 2020 Plan. Options may be granted at a price per share not less than 100 % of the fair market value at the date of grant. If the option is granted to a 10 % stockholder, then the purchase or exercise price per share shall not be less than 110 % of the fair market value per share of the common stock on the grant date. Options granted generally vest over a period of four years and have ten-year contractual terms. Stock Options Stock option activity under the Plans, including the EPA Program discussed below is as follows: Number of Weighted Weighted Intrinsic value Balance as of December 31, 2021 (1) 53,078 $ 7.74 6.78 Granted (2) 2,100 23.04 Cancelled and forfeited (3) ( 1,222 ) 16.66 Exercised ( 3,832 ) 1.39 Balance as of December 31, 2022 50,124 $ 8.65 6.05 $ 129,209 Vested and expected to vest as of December 31, 2022 (4) 40,549 $ 5.25 5.36 $ 129,209 Vested and exercisable as of December 31, 2022 31,042 $ 1.73 4.44 $ 122,355 (1) This includes 14.7 million options granted in December 2021 pursuant to the EPA Program. (2) All options granted during the year ended December 31, 2022, were granted pursuant to the EPA Program. (3) This includes 0.8 million options forfeited from the EPA program. (4) This includes 6.4 million options granted pursuant to the EPA Program that are currently expected to vest. None of the options granted pursuant to the EPA Program were vested and exercisable as of December 31, 2022 . Options with a weighted average fair value of $ 4.93 per share, $ 20.58 per share and $ 2.67 per share were granted during the year ended December 31, 2022, December 31, 2021 and December 31, 2020, respectively. The aggregate intrinsic value of options exercised during the years ended December 31, 2022, December 31, 2021 and December 31, 2020 was $ 42.0 million and $ 489.7 million and $ 3.5 million, respectively. Additional information regarding options outstanding as of December 31, 2022, is as follows: Range of Exercise Price per Share Number of Options Outstanding Weighted Average Exercise Price Weighted Average Remaining Contractual Life (Years) $ 0.64 2,414 $ 0.64 $ 0.32 $ 1.05 - $ 1.35 19,107 $ 1.29 $ 3.85 $ 2.38 10,112 $ 2.38 $ 6.56 $ 6.23 2,533 $ 6.23 $ 7.68 23.04 15,958 $ 23.04 $ 8.96 50,124 $ 8.65 $ 6.05 Stock-based compensation expense is based on the grant-date fair value. The Company recognizes compensation expense for awards with only service conditions on a straight-line basis over the requisite service period of the awards, which is generally the option vesting term of four years . Excluding options granted pursuant to the EPA Program, as of December 31, 2022 , the Company had stock-based compensation of $ 6.4 million related to unvested stock options not yet recognized that are expected to be recognized over an estimated weighted average period of 1.8 years. The following weighted average assumptions were used as inputs to the Monte Carlo simulation in determining the estimated grant-date fair value of the Company’s stock options for the year ended December 31, 2022: Year Ended December 31, 2022 2021 Volatility 98.69 % 112.49 % Risk-free interest rate 3.52 % 1.44 % Expected dividend — — Cost of equity 14.62 % 11.66 % Weighted average fair value at grant date $ 4.93 $ 20.58 All options granted during the years ended December 31, 2022 and December 31, 2021, were granted pursuant the EPA Program and were valued using a Monte Carlo simulation. The Monte Carlo simulation used in the valuation of the options required the Company to make assumptions and judgements about the variables used in the calculation including the expected term, volatility of the Company's common stock and cost of equity. The Company estimated expected term based on the midpoint between the time of vesting and the remaining time to expiration of the option. For options granted in December 2021, given the limited market trading history of the Company's common stock, volatility is based on a weighted blend of (i) the average volatility of peer companies within the automotive and energy storage industries multiplied by a ratio of the Company's volatility based on available stock price data as compared to the average volatility of the Company's peers over the same period and (ii) our implied volatility from exchange traded options. For options granted in December 2022, volatility is based on a blend of (i) the Company’s historical volatility from daily closing stock prices given increased trading history and (ii) the Company’s implied volatility from exchange traded options. Cost of equity is calculated using (i) risk-free rate, (ii) average peer group market beta and (iii) the market-risk premium. The following weighted average assumptions were used as inputs to the Black-Scholes Option Pricing Model in determining the estimated grant-date fair value of the Company’s stock options for the years ended December 31, 2020: Year Ended December 31, 2020 Volatility 70.00 % Risk-free interest rate 0.39 % Expected term (in years) 6.08 Expected dividend — Weighted average fair value at grant date $ 2.67 For options granted with only service conditions, the Company uses the simplified calculation of the expected life for the valuation of options, which takes into consideration the grant’s contractual life and vesting period and assumes that all options will be exercised between the vesting date and the contractual term of the option. Given the lack of a public market for the Company’s common stock prior to the Business Combination and the Company's minimal history as a public company subsequent to the Business Combination, the estimate for volatility is based on an average of the historical volatilities of the common stock of several entities with characteristics similar to those of the Company. Since these comparable companies operate in the same industry segment, the Company expects that it would share similar characteristics, such as risks profiles, volatility, capital intensity, clientele, and market growth patterns and drivers. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods corresponding with the expected life of the option. EPA Program In December 2021, the Company granted stock options for the purchase of an aggregate of approximately 14.7 million shares of the Company's Class A Common Stock to the Company's Chief Executive Officer and other members of the Company’s management team pursuant to the EPA Program that was approved by the Company's stockholders in December 2021. In December 2022, the remaining 2.1 million stock options under the EPA Program were granted to members of the Company's management team under the same terms as those in the initial grant in 2021, representing the final grant pursuant to the EPA Program approved in December 2021. The EPA Program consists of five equal tranches (each a “Tranche”) that vest if the Company meets certain business milestones (performance conditions) and stock price targets (market conditions). Business Milestones The compensation committee of the Board selected the following eleven business milestones for the EPA Program, of which one milestone must be achieved for each tranche. • Delivery of an A-sample battery cell that meets specifications agreed upon with an automaker • The validation by an auto maker of a completed B-sample battery cell (a B-sample battery cell is a functional, complete battery cell prototype produced from our pre-pilot or sample production line) • Delivery of at least 1-gigawatt hour (GWh) of battery cells to a single customer • Delivery of at least 3-gigawatt hour (GWh) of battery cells to each of three or more customers, with at least one of such customer being an auto maker • $5 billion in GAAP revenue over a period of trailing four quarters • $10 billion in GAAP revenue over a period of trailing four quarters • Total cumulative battery cell production of 500 GWh • Total cumulative battery cell production of 1,000 GWh • Adjusted EBITDA margin of at least 25% over four consecutive quarters • 10% of worldwide market share in automotive battery cells (excluding China) • 20% of worldwide market share in automotive battery cells (excluding China) Once a business milestone has been achieved, that business milestone will be considered achieved, even if later the Company does not maintain performance at that level. Stock Price Targets The stock price targets of the five tranches of the EPA Program are $ 60 , $ 120 , $ 180 , $ 240 and $ 300 . To meet the stock price targets, the stock price must be sustained and not merely momentarily achieved. Except in the case of a change in control, the Company’s stock price for the purposes of assessing the stock price target will be the 120-day trailing average closing price (based on trading days), but a stock price target will not be achieved unless the trailing average closing price of the last 30 trading days of such 120-trading day period also meets or exceeds the applicable stock price target. For a stock price target for any given Tranche to be achieved, the last day of the 120-day measurement period must occur on or after the date that the requisite number of business milestones have been achieved for such Tranche. Vesting Tranches Each of the five Tranches vest only if the Company achieves one of the business milestones (in addition to the business milestones already achieved in a prior Tranche) and achieves the applicable stock price target on or after the business milestone is achieved, within 10 years of the initial grants. Additionally, in order to vest in any Tranche, Participants generally must continue to provide service through the date of vesting in the same position, or a similar or higher role, as when the EPA Program awards are granted. Tranche Business Milestone Requirement Stock Price Target 1 Achievement of 1 business milestone $ 60 2 Achievement of 2 business milestones (inclusive of the business milestone applicable to Tranche 1) $ 120 3 Achievement of 3 business milestones (inclusive of the business milestone applicable to Tranche 2) $ 180 4 Achievement of 4 business milestones (inclusive of the business milestone applicable to Tranche 3) $ 240 5 Achievement of 5 business milestones (inclusive of the business milestone applicable to Tranche 4) $ 300 Change in Control In the event of a change in control of the Company, a portion of the EPA Program awards may also be eligible to vest; in such event, the business milestone requirement will not be applicable and the Company’s stock price for the purposes of the stock price targets will be the price per share paid in such change in control. In the event that the Company’s stock price by this measure falls between two stock price targets, linear interpolation between the two applicable stock price targets will be used to determine an additional portion of the EPA Program awards that will vest. Any portion of an EPA Program award that is not vested upon and after giving effect to a change in control will terminate. The Company accounts for the compensation expense associated with each tranche when it determines that achievement of a related business milestone is considered probable. As of December 31, 2022 , the two tranches were considered probable. For the years ended December 31, 2022 and 2021 , the Company recorded stock-based compensation expense of $ 49.4 and $ 2.4 million, respectively related to the EPA Program. As of December 31, 2022, the Company had approximatel y $ 65.3 million of total unrecognized stock-based compensation expense for the business milestones currently considered probable of achievement, which will be recognized over an estimated weighted-average period of 2.7 ye ars. As of December 31, 2022 , the Company had approximately $ 178.4 million of total unrecognized stock-based compensation expense for the business milestones currently considered not probable of achievement. Restricted Stock Units Restricted stock unit activity under the Plans are as follows: Number of Weighted Balance as of December 31, 2020 13,913 $ 8.94 Granted 2,082 30.28 Vested ( 5,027 ) 6.00 Forfeited ( 414 ) 10.97 Balance as of December 31, 2021 10,555 14.48 Granted 12,466 13.13 Vested ( 5,297 ) 12.75 Forfeited ( 1,161 ) 17.18 Balance as of December 31, 2022 16,563 13.79 The fair value of restricted stock units which vested during the year ended December 31, 2022 and December 31, 2021 was $ 65.5 million and $ 198.0 million, respectively. No restricted stock units vested during the year ended December 31, 2020. As of December 31, 2022 , unrecognized compensation costs related to restricted stock units was $ 207.9 million and is expected to be recognized over a weighted average period of 2.9 years. Stock-Based Compensation Expense Total stock-based compensation expense recognized in the accompanying Consolidated Statements of Operations and Comprehensive Loss for all equity awards is as follows (amounts in thousands): Year Ended December 31, 2022 2021 2020 Research and development $ 62,892 $ 29,653 $ 9,889 General and administrative 64,218 22,522 7,135 Total stock-based compensation expense $ 127,110 $ 52,175 $ 17,024

Earnings (Loss) Per Share

Earnings (Loss) Per Share	12 Months Ended
	Dec. 31, 2022
Earnings Per Share [Abstract]
Earnings (Loss) Per Share	10. Earnings (Loss) Per Share Basic net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock outstanding during the period. Diluted earnings per share adjusts basic earnings per share for the potentially dilutive impact of stock options and warrants. As the Company has reported a loss for the year ended December 31, 2022, potentially dilutive securities including stock options and warrants, are antidilutive and accordingly, basic net loss per share equals diluted net loss per share. The following table sets forth the computation of basic and diluted loss per Class A Common Stock and Class B Common Stock (amounts in thousands, except per share amounts): Year Ended December 31, 2022 2021 2020 Numerator: Net loss attributable to common stockholders - Basic $ ( 411,907 ) $ ( 45,966 ) $ ( 1,681,777 ) Less: Change in fair value of assumed common stock warrant liabilities — ( 168,674 ) — Net loss attributable to common stockholders - Diluted $ ( 411,907 ) $ ( 214,640 ) $ ( 1,681,777 ) Denominator: Weighted average Class A and Class B Common Stock outstanding- Basic 432,973 404,259 252,144 Effect of dilutive securities — 5,250 — Weighted average Class A and Class B Common Stock outstanding - Diluted 432,973 409,509 252,144 Net loss per share attributable to Class A and Class B Common stockholders - Basic $ ( 0.95 ) $ ( 0.11 ) $ ( 6.67 ) Net loss per share attributable to Class A and Class B Common stockholders - Diluted $ ( 0.95 ) $ ( 0.52 ) $ ( 6.67 ) The following table presents the potential common stock outstanding that was excluded from the computation of diluted net loss per share of common stock as of the periods presented because including them would have been antidilutive (amounts in thousands): Year Ended December 31, 2022 2021 2020 Warrants — — 18,150 Options outstanding 50,124 53,078 55,316 Restricted stock units 16,563 10,555 13,913 VGA contingent purchase commitment (1) — — 15,221 Total 66,687 63,633 102,600 (1) This refers to VGA’s commitment to purchase 15.2 million shares of Class A Common Stock for $ 100.0 million subject to certain conditions including the achievement of a specified technical milestone by March 31, 2021. All shares were issued subsequent to the fulfillment of these conditions.

Joint Venture and Redeemable No

Joint Venture and Redeemable Non-Controlling Interest	12 Months Ended
	Dec. 31, 2022
Joint Venture And Non Controlling Interest [Abstract]
Joint Venture and Redeemable Non-Controlling Interest	Note 11. Joint Venture and Redeemable Non-Controlling Interest As described in Note 2, Summary of Significant Accounting Policies, in September 2018, the Company entered into a JVA with VWGoA and VGA and formed QSV. The Company determined the entity was a VIE with a related party, and the Company’s operations were more closely associated with QSV. As such, the Company consolidates QSV for financial reporting purposes, and a non-controlling interest is recorded for VGA’s interest in the net assets and operations of QSV's operations to the extent of the VGA investment. The Company’s Consolidated Balance Sheets includes $ 3.4 million cash and cash equivalents, of QSV both as of December 31, 2022 and December 31, 2021. Although the Company has consolidated the net assets of QSV, it has no right to the use of those assets for its standalone operations. The following table sets forth the change in redeemable non-controlling interest for years ended December 31, 2022, 2021 and 2020 (amounts in thousands): Redeemable Non-Controlling Balance as of December 31, 2019 $ 1,710 Net loss attributable to redeemable non-controlling interest in QSV ( 6 ) Balance as of December 31, 2020 $ 1,704 Net loss attributable to redeemable non-controlling interest in QSV ( 11 ) Balance as of December 31, 2021 $ 1,693 Net income attributable to redeemable non-controlling interest in QSV 11 Balance as of December 31, 2022 $ 1,704 In May 2020, the Company amended the JVA and other related agreements regarding QSV in connection with VGA’s investment of $ 200.0 million in the Company’s Series F convertible preferred stock. The Company determined the amendments represented a reconsideration event and determined that QSV is still a variable interest entity. As the significance and nature of the business of QSV continues to be more aligned with the core business of the Company and the Company continues to absorb a majority of the variability associated with QSV’s anticipated economic performance, the Company continues to be the related party most closely associated with QSV. In September 2020, the Company entered into an agreement with VWGoA under which the Company agreed to reserve $ 134.0 million from the aggregate proceeds of the Series F Preferred Stock financings and the Business Combination to fund its expected equity contributions to QSV, which amounts are included in cash and cash equivalents and marketable securities in the accompanying Consolidated Balance Sheets as of December 31, 2022 and 2021 .

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Income Taxes	12. Income Taxes The Company has no domestic provision for income taxes for the years ended December 31, 2022, 2021 and 2020 . The Company has no domestic current tax expense from losses generated in the U.S. and no deferred expense from the valuation allowance. The Company established a foreign subsidiary in Japan during the year ended December 31, 2021. The foreign tax provision for the year ended December 31, 2022, and December 31, 2021 is not material. A reconciliation from U.S. statutory rate of 21 % to the effective rate is as follows: Year Ended December 31, 2022 2021 2020 Federal Statutory rate 21.0 % 21.0 % 21.0 % State tax expense 7.0 % 7.1 % 0.0 % Stock-based compensation 1.7 % 349.5 % 0.0 % Change in fair value of assumed common stock warrant liabilities 0.0 % 103.1 % ( 7.3 %) Research and development tax credit 2.7 % 41.5 % 0.2 % Permanent tax items ( 0.1 %) ( 7.1 %) ( 0.2 %) State rate differential - change in apportionment 0.0 % 4.4 % ( 0.1 %) Prior year deferred true-up 4.6 % 2.5 % 0.1 % Change in fair value of Series F tranche liabilities 0.0 % 0.0 % ( 12.5 %) Sec. 162(m) wage limitation ( 2.2 %) ( 113.9 %) ( 0.1 %) Change to valuation allowance ( 34.7 %) ( 408.1 %) ( 1.1 %) Effective tax rate 0.0 % 0.0 % 0.0 % Significant components of the Company’s net deferred tax assets as of December 31, 2022 and 2021, are as follows (amounts in thousands): Year Ended December 31, 2022 2021 Deferred tax assets: Net operating losses $ 336,617 $ 257,426 Tax credits 58,476 35,149 Accruals and stock-based compensation 28,152 10,479 Lease liability 30,571 20,234 Section 174 capitalized research & development 45,369 — Intangibles — 685 Gross deferred tax assets 499,185 323,973 Valuation allowance ( 438,212 ) ( 293,211 ) Total deferred tax assets $ 60,973 $ 30,762 Deferred tax liabilities: Right of use assets $ ( 24,450 ) $ ( 18,999 ) Intangibles ( 561 ) — Fixed assets ( 35,962 ) ( 11,763 ) Total deferred tax liabilities ( 60,973 ) ( 30,762 ) Total net deferred tax assets $ — $ — Recognition of deferred tax assets is appropriate when realization of such assets is more likely than not. Based upon the weight of available evidence, which includes the Company’s historical operating performance, cumulative net losses, and projected future losses, the Company has provided a full valuation allowance against its deferred tax assets. The Company’s valuation allowance increased by $ 145.0 million, $ 187.4 million and $ 20.1 million for the years ended December 31, 2022, 2021 and 2020 , respectively. A reconciliation of the beginning and ending balances of the valuation allowance is as follows (amounts in thousands): Year Ended December 31, 2022 2021 2020 Beginning of the year $ ( 293,211 ) $ ( 105,781 ) $ ( 85,677 ) Increase ( 145,001 ) ( 187,430 ) ( 20,104 ) End of the year $ ( 438,212 ) $ ( 293,211 ) $ ( 105,781 ) As of December 31, 2022 , the Company had federal and state net operating loss carryforwards of approximately $ 1.20 billion and $ 1.19 billion, respectively. The federal net operating loss carryforwards of $ 170.2 million generated prior to 2018 will expire at various dates beginning in 2030 , if not utilized. We have federal net operating loss carryforwards of $ 1.03 billion, which can be carried forward indefinitely. The state net operating loss carryforwards will expire at various dates beginning in 2030, if not utilized. Section 382 and Section 383 of the Internal Revenue Code and similar provisions under state law has limitations on federal and state net operating loss carryforwards and research and development credit carryforwards. The Tax Reform Act contains provisions that limit the federal net operating loss carryforwards that may be used in any given year in the event of special occurrences, including significant ownership changes. A Section 382 “ownership change” generally occurs if one or more stockholders or groups of stockholders, who own at least 5% of the Company’s stock, increase their ownership by more than 50 percentage points over their lowest ownership percentage within a rolling three-year period. The Company performed the analysis and determined that it has experienced an ownership change in December 2010 and in August 2012 as a result of the preferred stock financing rounds. The federal and state net operating loss carryforwards and research and development credit carryforwards are not subject to significant limitations under Section 382 and Section 383 of the Internal Revenue Code and similar provisions under state law. As of December 31, 2022 , the Company also has federal and California research and development credits of $ 68.4 million and $ 48.5 million, respectively. The federal tax credit carryforwards will expire beginning in 2031 , if not utilized. The state tax credit carryforwards do not expire. The Company records unrecognized tax benefits in accordance with ASC 740-10, Income Taxes . ASC 740-10 which prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of uncertain tax positions taken or expected to be taken in the Company’s income tax return and also provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition. A reconciliation of the beginning and ending balances of unrecognized tax benefits is as follows (amounts in thousands): Year Ended December 31, 2022 2021 2020 Beginning of the year $ 32,172 $ 6,575 $ 7,076 Increase—current year positions 12,388 20,633 1,553 Decrease—current year positions ( 5,056 ) — — Increase—prior year positions 13,298 5,056 193 Decrease—prior year positions — ( 92 ) ( 2,247 ) End of the year $ 52,802 $ 32,172 $ 6,575 Due to the Company’s full valuation allowance, the unrecognized tax benefits would not materially impact the Company’s effective tax rate when recognized. The Company does not anticipate the total amounts of unrecognized tax benefits will significantly increase or decrease in the next 12 months. The Company’s policy is to classify interest and penalties associated with uncertain tax positions, if any, as a component of its income tax provision. For the years ended December 31, 2022, 2021 and 2020 , the Company had no interest or penalties related to unrecognized tax benefits. The federal and state income tax returns are open under the statute of limitations subject to tax examinations for the tax years ended December 31, 2019 through December 31, 2021 and December 31, 2018 through December 31, 2021, respectively. To the extent the Company has tax attribute carryforwards, the tax years in which the attribute was generated may still be adjusted upon examination by the IRS or state tax authorities to the extent utilized in a future period.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The Company’s consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) as determined by the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) and pursuant to the regulations of the U.S. Securities and Exchange Commission (“SEC”). On November 25, 2020 , the Company consummated the Business Combination Agreement dated September 2, 2020 , with Legacy QuantumScape surviving the merger as a wholly owned subsidiary of the Company. At the effective time of the Merger, and subject to the terms and conditions of the Business Combination Agreement, each share of Legacy QuantumScape Class A common stock, par value $ 0.0001 per share, and each share of the Legacy QuantumScape Preferred Stock that was convertible into a share of Legacy QuantumScape Class A Common Stock, was canceled and converted into the right to receive the number of shares of the Company’s Class A Common Stock, $ 0.0001 par value per share (the “Class A Common Stock”), equal to 4.02175014920 (the “Exchange Ratio”), and each share of Legacy QuantumScape Class B Common Stock, par value $ 0.0001 per share, and each share of the Legacy QuantumScape Preferred Stock that was convertible into a share of Legacy QuantumScape Class B Common Stock was canceled and converted into the right to receive the number of shares of the Company’s Class B Common Stock, $ 0.0001 par value per share equal to the Exchange Ratio. Pursuant to the Business Combination Agreement, the merger between Merger Sub and Legacy QuantumScape was accounted for as a reverse recapitalization in accordance with U.S. GAAP (the “Reverse Recapitalization”). Under this method of accounting, Kensington was treated as the “acquired” company and Legacy QuantumScape was treated as the acquirer for financial reporting purposes. Legacy QuantumScape was determined to be the accounting acquirer based on the following predominant factors: • Legacy QuantumScape’s shareholders have the largest portion of voting rights in the Company; • the Company's Board of Directors (the “Board”) and management are primarily composed of individuals associated with Legacy QuantumScape; and • Legacy QuantumScape was the larger entity based on historical operating activity and Legacy QuantumScape has the larger employee base at the time of the Business Combination. Accordingly, for accounting purposes, the Reverse Recapitalization was treated as the equivalent of Legacy QuantumScape issuing stock for the net assets of Kensington, accompanied by a recapitalization. The net assets of Kensington were stated at historical cost, with no goodwill or other intangible assets recorded.
Principles of Consolidation	Principles of Consolidation The Company’s policy is to consolidate all entities that it controls by ownership of a majority of the outstanding voting stock. In addition, the Company consolidates entities that meet the definition of a variable interest entity (“VIE”) for which the Company is the related party most closely associated with and is the primary beneficiary. The primary beneficiary is the party who has the power to direct the activities of a VIE that most significantly impact the entity’s economic performance and who has an obligation to absorb losses of the entity or a right to receive benefits from the entity that could potentially be significant to the entity. For consolidated entities that are less than wholly owned, the third party’s holding of an equity interest is presented as redeemable non-controlling interests in the Company’s Consolidated Balance Sheets and Consolidated Statements of Redeemable Non-Controlling Interest and Stockholders’ Equity. The portion of net earnings (loss) attributable to the redeemable non-controlling interests is presented as net income (loss) attributable to non-controlling interests in the Company’s Consolidated Statements of Operations and Comprehensive Income (Loss). The Company was a single-legal entity prior to becoming a partner with Volkswagen in QSV Operations LLC (“QSV”). As noted in the section titled “ Joint Venture and Redeemable Non-Controlling Interest ” below, the Company determined QSV was a VIE for which it was required to consolidate the operations upon its formation in 2018. The Company continued to consolidate the operations of the QSV in 2022 as the determination of the VIE has not changed. All intercompany accounts and transactions are eliminated in consolidation.
Use of Estimates	Use of Estimates The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of commitments and contingencies at the date of the financial statements as well as reported amounts of expenses during the reporting periods. Estimates made by the Company include, but are not limited to, those related to the valuation of common stock prior to the Business Combination, valuation of awards under the Extraordinary Performance Award Program (the “EPA Program”), and valuation of Assumed Common Stock Warrants among others. The Company bases these estimates on historical experience and on various other assumptions that it believes are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying amounts of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates.
Joint Venture and Redeemable Non-Controlling Interest	Joint Venture and Redeemable Non-Controlling Interest QSV was incorporated as a limited liability company in 2018. Volkswagen Group of America, Inc. (“VWGoA”), Volkswagen Group of America Investments, LLC (“VGA”) and QuantumScape executed a Joint Venture Agreement (“JVA”), effective September 2018, with the goal of jointly establishing a manufacturing facility to produce the pilot line of the Company’s product through QSV. In connection with this agreement, the parties also have entered into two operating agreements: (i) the Limited Liability Company Agreement of QSV to govern the respective rights and obligations as members of QSV and (ii) the Common IP License Agreement for the Company to license certain intellectual property pertaining to automotive battery cells as defined in the JVA to VWGoA, VGA and QSV. Volkswagen is a related party stockholder (approximately 21.5 % and 19.8 % voting interest holder of the Company as of December 31, 2022 and 2021 , respectively). Upon the effectiveness of the JVA, each party contributed $ 1.7 million in cash to capitalize QSV in exchange for 50 % equity interests. The joint venture is considered a VIE with a related party and therefore the related party whose business is more closely related to the planned operations of the joint venture is required to consolidate the operations. The Company determined its operations were most closely aligned with the operations of the joint venture and therefore has consolidated the results of QSV’s operations in its Consolidated Balance Sheets, Consolidated Statements of Operations and Comprehensive Income (Loss) and Consolidated Statements of Redeemable Non-Controlling Interest and Stockholders’ Equity. QSV had minimal operations through December 31, 2022. The Company classifies non-controlling interests with redemption features that are not solely within the control of the Company within temporary equity on the Company’s Consolidated Balance Sheets in accordance with ASC 480-10-S99-3A, SEC Staff Announcement: Classification and Measurement of Redeemable Securities (“ASC 480-10-S99-3A”). The non-controlling interest was recorded outside of stockholders’ equity because the non-controlling interest provides the holder with put rights in the event of, amongst others, (i) the failure by the Company to meet specified development milestones within certain timeframes, (ii) the parties to the JVA cannot agree to certain commercial terms within certain timeframes, or (iii) a change of control of the Company, which such events are considered not solely within the Company’s control. The Company adjusts redeemable non-controlling interests for the portion of net loss attributable to the redeemable non-controlling interests. As of December 31, 2022 , the redeemable non-controlling interest is equivalent to the value of Volkswagen's interest in the joint venture. The commercialization timeline originally contemplated in 2018 by the joint venture agreements, and by subsequent amendments, has changed, and as of the time of our filing of this annual report on Form 10-K, certain milestones contemplated by the joint venture agreements were not met. As a result, Volkswagen now has the right to exercise its put rights. If Volkswagen exercises such rights, the joint venture with Volkswagen and Volkswagen’s commitments to purchase output capacity from the joint venture would terminate, and we would be obligated to purchase Volkswagen’s interest in the joint venture for its book value. As of December 31, 2022, the book value of this interest was approximately $ 1.7 million and is recorded as a redeemable non-controlling interest in our Consolidated Balance Sheets. To date, Volkswagen has not informed us of any intention to exercise their put rights.
Concentrations of Credit Risk	Concentrations of Credit Risk Financial instruments that potentially subject the Company to credit risk consist principally of cash and cash equivalents and marketable securities. As of December 31, 2022 and 2021 , approximately $ 107.4 million and $ 227.8 million of our total cash and cash equivalents and marketable securities, are held in U.S. money market funds, and $ 610.5 million and $ 722.3 million are invested in U.S. government and agency securities, respectively. The Company seeks to mitigate its credit risk with respect to cash and cash equivalents and marketable securities by making deposits with large, reputable financial institutions and investing in high credit rated shorter-term instruments.
Cash and Cash Equivalents and Restricted Cash	Cash and Cash Equivalents and Restricted Cash Management considers all highly liquid investments with original maturities of three months or less to be cash equivalents. Restricted cash is maintained under an agreement that legally restricts the use of such funds and is reported within other assets as the date of availability or disbursement for all restricted cash is more than one year from December 31, 2022. Restricted cash is comprised of $ 17.5 million, as of both December 31, 2022 and December 31, 2021 , all of which is pledged as a form of security for the Company’s lease agreements for its headquarters and pre-pilot manufacturing facilities.
Marketable Securities	Marketable Securities The Company’s investment policy is consistent with the definition of available-for-sale securities. The Company does not buy and hold securities principally for the purpose of selling them in the near future. The Company’s policy is focused on the preservation of capital, liquidity, and return. From time to time, the Company may sell certain securities, but the objectives are generally not to generate profits on short-term differences in price. These securities are carried at estimated fair value with unrealized gains and losses included in other comprehensive gain/loss in stockholders’ equity until realized. Gains and losses on marketable security transactions are reported on the specific-identification method. Dividend and interest income are recognized when earned.
Fair Value Measurement	Fair Value Measurement The Company applies fair value accounting for all financial assets and liabilities measured on a recurring and nonrecurring basis. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. The accounting guidance established a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, used to determine the fair value of its financial instruments. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. • Level 1 – Quoted prices in active markets for identical assets or liabilities that the entity has the ability to access. • Level 2 – Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets and liabilities. • Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets and liabilities.
Property and Equipment	Property and Equipment Property and equipment are recorded at historical cost, less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful life of the related asset. Improvements that increase functionality of the fixed asset are capitalized and depreciated over the asset’s remaining useful life. Deposits for purchases of property and equipment are included in construction-in-progress. Construction-in-progress is not depreciated until the asset is placed in service. Fully depreciated assets are retained in property and equipment, net, until removed from service. The estimated useful lives of assets are generally as follows: Computer equipment, hardware, and software 3 - 5 years Furniture and fixtures 7 - 10 years Machinery and equipment 3 - 10 years Leasehold improvements Shorter of the lease term (including estimated renewals) or the estimated useful lives of the improvements
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets The Company evaluates the carrying value of long-lived assets when indicators of impairment exist. The carrying value of a long-lived asset is considered impaired when the estimated separately identifiable, undiscounted cash flows from such an asset are less than the carrying value of the asset. In that event, a loss is recognized based on the amount by which the carrying value exceeds the fair value of the long-lived asset. Fair value is determined primarily using the estimated cash flows discounted at a rate commensurate with the risk involved. The long-lived assets outside of U.S. are not material as of December 31, 2022. There was no material impairment charge in the year ended December 31, 2021, or December 31, 2020. During the year ended December 31, 2022, the Company wrote off approximately $ 13.7 million of equipment and incurred cancellation charges of approximately $ 2.8 million to focus on process and equipment development designed to deliver higher throughput with fewer processing steps. These charges are recorded in Research and Development expense in the Consolidated Statements of Operations and Comprehensive Income (Loss).
Leases	Leases The Company classifies arrangements meeting the definition of a lease as operating or financing leases, and leases are recorded on the Consolidated Balance Sheets as both a right-of-use (“ROU”) asset and lease liability, calculated by discounting fixed lease payments over the lease term at the rate implicit in the lease or the Company’s incremental borrowing rate which is the rate incurred to borrow on a collateralized basis over a similar term. Lease liabilities are increased by interest and reduced by payments each period, and the ROU asset is reduced over the lease term. For operating leases, interest on the lease liability and the non-cash lease expense result in straight-line rent expense over the lease term. For finance leases, interest on the lease liability and the amortization of the ROU asset results in front-loaded expense over the lease term. Variable lease expenses, including common maintenance fees, insurance and property tax, are recorded when incurred. In calculating the right-of-use asset and lease liability, the Company elects to combine lease and non-lease components for all classes of assets, and elects to exclude short-term leases having terms of 12 months or less.
Assumed Common Stock Warrants Liability	Assumed Common Stock Warrants Liability The Company assumed 11,499,989 Public Warrants and 6,650,000 Private Placement Warrants upon the Business Combination, all of which were issued in connection with Kensington’s initial public offering (other than 75,000 Private Placement Warrants that were issued in connection with the closing of the Business Combination, which are referred to as the Working Capital Warrants) and entitled each holder to purchase one share of Class A Common Stock at an exercise price of $ 11.50 per share. The Company evaluated the Assumed Common Stock Warrants under ASC 815-40, Derivatives and Hedging—Contracts in Entity’s Own Equity ( “ ASC 815-40 ” ) , and concluded they did not meet the criteria to be classified in stockholders’ equity. Specifically, the exercise of the Assumed Common Stock Warrants could have been settled in cash upon the occurrence of a tender offer or exchange that involves 50 % or more of our holders of Class A Common Stock. Because not all of the voting stockholders need to participate in such tender offer or exchange to trigger the potential cash settlement and the Company does not control the occurrence of such an event, the Company concluded that the Assumed Common Stock Warrants did not meet the conditions to be classified in equity. Since the Assumed Common Stock Warrants meet the definition of a derivative under ASC 815, the Company recorded these warrants as liabilities on the Consolidated Balance Sheets at fair value, with subsequent changes in their respective fair values recognized in the change in fair value of Assumed Common Stock Warrant liabilities within the Consolidated Statement of Operations and Comprehensive Income (Loss) at each reporting date prior to exercise or redemption. As described in Note 7, Commitments and Contingencies, below, the Company announced that it had elected to redeem its outstanding Public Warrants and Private Placement Warrants in July and August 2021, respectively. As of December 31, 2021, no Public Warrants or Private Placement Warrants were outstanding. As of December 31, 2020, 11,499,989 Public Warrants and 6,650,000 Private Placement Warrants were outstanding.
Segments	Segments Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the Chief Operating Decision Maker (“CODM”) in deciding how to allocate resources to an individual segment and in assessing performance. The Company’s CODM is its Chief Executive Officer. The Company has determined that it operates in one operating segment and one reportable segment, as the CODM reviews financial information presented on a consolidated basis for purposes of making operating decisions, allocating resources, and evaluating financial performance.
Research and Development Cost	Research and Development Cost Costs related to research and development are expensed as incurred.
General and Administrative Expenses	General and Administrative Expenses General and administrative expenses represent costs incurred by the Company in managing the business, including salary, benefits, incentive compensation, marketing, insurance, professional fees and other operating costs associated with the Company’s non-research and development activities.
Stock-Based Compensation	Stock-Based Compensation The Company measures and recognizes compensation expense for all stock-based awards made to employees, directors, and non-employees, including stock options, restricted share units and restricted shares, based on estimated fair values recognized over the requisite service period. The fair values of options granted with only service conditions are estimated on the grant date using the Black-Scholes option pricing model. This valuation model for stock-based compensation expense requires the Company to make assumptions and judgments about the variables used in the calculation, including the expected term (weighted-average period of time that the options granted are expected to be outstanding), the volatility of the Company’s common stock, and an assumed risk-free interest rate. The Company accounts for forfeitures when they occur. The fair values of options granted with performance (e.g., business milestone) and market conditions (e.g., stock price target) are estimated at the grant date using a Monte Carlo simulation model. The model determined the grant date fair value of each vesting tranche and the future date when the market condition for such tranche is expected to be achieved. The Monte Carlo valuation requires the Company to make assumptions and judgements about the variables used in the calculation including the expected term, volatility of the Company's common stock, an assumed risk-free interest rate, and cost of equity. For performance-based awards with a vesting schedule based entirely on the attainment of both performance and market conditions, each quarter the Company assesses whether it is probable that it will achieve each performance condition that has not previously been achieved or deemed probable of achievement and if so, the future time when the Company expects to achieve that business milestone, or its “expected business milestone achievement time.” When the Company first determines that a business milestone has become probable of being achieved, the Company allocates the entire expense for the related tranche over the number of quarters between the grant date and the then-applicable “expected vesting date,” which represents the requisite service period. The requisite service period at any given time is generally the period between the grant date and the later of (i) the expected time when the performance condition will be achieved (if the related performance condition has not yet been achieved) and (ii) the expected time when the market condition will be achieved (if the related market condition has not yet been achieved). The Company immediately recognizes a cumulative catch-up expense for all accumulated expense for the quarters from the grant date through the quarter in which the performance condition was first deemed probable of being achieved. Each quarter thereafter, the Company recognizes the then-remaining expense for the tranche through the end of the requisite service period except that upon vesting of a tranche, all remaining expense for that tranche is immediately recognized. The Company accounts for forfeitures when they occur. The Company estimates the fair value of restricted stock units based on the closing price of the Company’s Class A Common Stock on the date of grant. The Company’s 2020 Employee Stock Purchase Plan (“ESPP”) is compensatory in accordance with ASC 718-50-25. The Company measures and recognizes compensation expense for shares to be issued under the ESPP based on estimated grant date fair value recognized on a straight-line basis over the offering period. The first offering period for the ESPP commenced in June 2021. The ESPP provides eligible employees with the opportunity to purchase shares of the Company’s Class A Common Stock at a discount through payroll deductions. A participant may purchase a maximum of 1,000 shares of Class A Common Stock during each six-month offering period. As of December 31, 2022 , 11.3 million shares of Class A Common Stock were reserved for future issuance under the ESPP. There were 510,993 shares purchased under the ESPP during the year ended December 31, 2022 .
Income Taxes	Income Taxes The Company accounts for income taxes under an asset and liability approach. Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes and operating loss carryforwards, measured by applying currently enacted tax laws. Valuation allowances are provided when necessary to reduce net deferred tax assets to an amount that is more likely than not to be realized. The Company recognizes tax liabilities based upon its estimate of whether, and the extent to which, additional taxes will be due when such estimates are more likely than not to be sustained. An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained.
Net Loss per Share of Common Stock	Net Loss per Share of Common Stock Basic net income (loss) per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted earnings (loss) per share adjusts basic earnings per share for the potentially dilutive impact of stock options and warrants. For warrants that are liability-classified, during periods when the impact is dilutive, the Company assumes share settlement of the instruments as of the beginning of the reporting period and adjusts the numerator to remove the change in fair value of the warrant liability and adjusts the denominator to include the dilutive shares calculated using the treasury stock method.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
Summary of Property and Equipment and Their Estimated Useful Lives of Assets	The estimated useful lives of assets are generally as follows: Computer equipment, hardware, and software 3 - 5 years Furniture and fixtures 7 - 10 years Machinery and equipment 3 - 10 years Leasehold improvements Shorter of the lease term (including estimated renewals) or the estimated useful lives of the improvements

Fair Value Measurement (Tables)

Fair Value Measurement (Tables)	12 Months Ended
	Dec. 31, 2022
Summary of Financial Assets and Liabilities Subject to Fair Value Measurements on Recurring Basis	The Company’s financial assets and liabilities subject to fair value measurements on a recurring basis and the level of inputs used for such measurements were as follows (amounts in thousands): Fair Value Measured as of December 31, 2022 Level 1 Level 2 Total Assets included in: Money market funds (1) $ 107,439 $ — $ 107,439 Commercial paper (2) — 104,231 104,231 U.S. government and agency securities (2) — 610,450 610,450 Corporate notes and bonds (2) — 188,658 188,658 Total fair value $ 107,439 $ 903,339 $ 1,010,778 Fair Value Measured as of December 31, 2021 Level 1 Level 2 Total Assets included in: Money market funds (1) $ 227,826 $ — $ 227,826 Commercial paper (2) — 233,400 233,400 U.S. government securities (2) — 722,310 722,310 Corporate notes and bonds (2) — 257,384 257,384 Total fair value $ 227,826 $ 1,213,094 $ 1,440,920 (1) Money market funds are included in cash and cash equivalents on the Consolidated Balance Sheets. (2) Marketable securities consist of commercial paper, U.S. government and agency securities, corporate notes and bonds. As of December 31, 2022 and 2021 , marketable securities with original maturities of three months or less of $ 77.0 million and $ 86.1 million, respectively, are included in cash and cash equivalents on the Consolidated Balance Sheets.
Summary of Major Security Type Assets That Measured at Fair Value on Recurring Basis	The fair value as of December 31, 2022 and 2021, are as follows (amounts in thousands): December 31, 2022 Amortized Cost Gross Gross Fair Value Level 1 securities Money market funds $ 107,439 $ — $ — $ 107,439 Level 2 securities Commercial paper 104,231 — — 104,231 U.S. government and agency securities 620,660 24 ( 10,234 ) 610,450 Corporate notes and bonds 196,321 — ( 7,663 ) 188,658 Total $ 1,028,651 $ 24 $ ( 17,897 ) $ 1,010,778 December 31, 2021 Amortized Cost Gross Gross Fair Value Level 1 securities Money market funds $ 227,826 $ — $ — $ 227,826 Level 2 securities Commercial paper 233,400 — — 233,400 U.S. government securities 724,554 — ( 2,244 ) 722,310 Corporate notes and bonds 259,348 — ( 1,964 ) 257,384 Total $ 1,445,128 $ — $ ( 4,208 ) $ 1,440,920
Summary of Additional Information Gross Unrealized Losses and Fair Value By Major Security For Marketable Securities	The following tables display additional information regarding gross unrealized losses and fair value by major security type for the 95 and 118 marketable securities in unrealized loss position as of December 31, 2022 and 2021, respectively (amounts in thousands): December 31, 2022 Less than 12 Consecutive Months 12 Consecutive Months or Longer Total Gross Fair Value Gross Fair Value Gross Fair Value U.S. government and agency securities $ ( 521 ) $ 231,047 $ ( 9,713 ) $ 336,517 $ ( 10,234 ) $ 567,564 Corporate notes and bonds ( 261 ) 18,585 ( 7,402 ) 170,073 ( 7,663 ) 188,658 Total $ ( 782 ) $ 249,632 $ ( 17,115 ) $ 506,590 $ ( 17,897 ) $ 756,222 December 31, 2021 Less than 12 Consecutive Months 12 Consecutive Months or Longer Total Gross Fair Value Gross Fair Value Gross Fair Value U.S. government securities $ ( 2,239 ) $ 700,318 $ ( 5 ) $ 17,011 $ ( 2,244 ) $ 717,329 Corporate notes and bonds ( 1,964 ) 257,384 — — ( 1,964 ) 257,384 Total $ ( 4,203 ) $ 957,702 $ ( 5 ) $ 17,011 $ ( 4,208 ) $ 974,713
Summary of Estimated Amortized Cost and Fair Value of Available-for-Sale Securities by Contractual Maturity	The estimated amortized cost and fair value of available-for-sale securities by contractual maturity as of December 31, 2022, are as follows (amounts in thousands): December 31, 2022 Amortized Cost Fair Value Due within one year $ 803,011 $ 797,053 Due after one year and through five years 225,640 213,725 Total $ 1,028,651 $ 1,010,778
Series F Convertible Preferred Stock
Schedule of Reconciliation of Warrants and Tranche Liabilities Measured and Recorded at Fair Value on Recurring Basis Using Significant Unobservable Inputs	The following table presents the reconciliation of the Series F convertible preferred tranche liabilities measured and recorded at fair value on a recurring basis using the significant unobservable inputs described above (amounts in thousands): Fair Value Balance as of December 31, 2019 $ — Issuance and re-measurement loss recorded in other expense 999,865 Issuance of Legacy QuantumScape Series F Preferred Stock - tranche shares 3 and 4 ( 484,471 ) Reclassification to additional paid-in capital upon Closing of the Business Combination - tranche shares 1 and 2 ( 515,394 ) Balance as of December 31, 2020 $ —

Balance Sheet Components (Table

Balance Sheet Components (Tables)	12 Months Ended
	Dec. 31, 2022
Balance Sheet Related Disclosures [Abstract]
Schedule of Property and Equipment	Property and equipment as of December 31, 2022 and 2021, consisted of the following (amounts in thousands): December 31, 2022 2021 Computer equipment, hardware, and software $ 6,784 $ 2,740 Furniture and fixtures 57,771 15,116 Leasehold improvements 72,201 23,192 Machinery and equipment 120,618 66,953 Construction-in-progress 108,585 101,420 Property and equipment, gross 365,959 209,421 Accumulated depreciation and amortization ( 70,025 ) ( 43,238 ) Property and equipment, net $ 295,934 $ 166,183
Schedule of Accrued Liabilities	Accrued liabilities as of December 31, 2022 and 2021, consisted of the following (amounts in thousands): December 31, 2022 2021 Accrued property and equipment $ 3,152 $ 1,815 Accrued facilities expense 1,106 1,637 Other 3,219 2,626 Accrued liabilities $ 7,477 $ 6,078
Schedule Of Other Liabilities	Other liabilities as of December 31, 2022 and 2021, consisted of the following (amounts in thousands): December 31, 2022 2021 Long-term advance payments $ 2,615 $ 315 Asset retirement obligation 5,873 — Other liabilities $ 8,488 $ 315

Leases (Tables)

Leases (Tables)	12 Months Ended
	Dec. 31, 2022
Leases [Abstract]
Summary of Lease Related Expense	The components of lease-related expense are as follows (amounts in thousands): Year Ended December 31, Lease costs 2022 2021 2020 Finance lease costs: Amortization of right-of-use assets $ 2,873 $ 1,915 $ — Interest on lease liabilities 2,399 1,419 — Operating lease costs 9,082 3,016 2,143 Variable lease costs 2,330 530 409 Total lease expense $ 16,684 $ 6,880 $ 2,552
Summary of Supplemental Cash Flow Information Related to Leases	The components of supplemental cash and noncash information related to leases are as follows (amounts in thousands): Year Ended December 31, 2022 2021 2020 Operating outgoing cash flows - finance lease $ 1,610 $ 330 $ — Financing outgoing cash flows - finance lease 809 73 — Financing (incoming) cash flows - finance lease — ( 5,580 ) — Operating outgoing cash flows - operating lease 4,673 2,711 1,994 Right-of-use assets obtained in exchange for new finance lease liabilities — 32,802 — Right-of-use assets obtained in exchange for new operating lease liabilities 28,845 26,778 —
Summary of Additional Information for Leases	The table below displays additional information for leases: December 31, 2022 2021 Finance lease Weighted-average remaining lease term - finance lease (in years) 9.8 10.8 Weighted-average discount rate - finance lease 6.06 % 6.06 % Operating lease Weighted-average remaining lease term - operating lease (in years) 9.6 10.7 Weighted-average discount rate - operating lease 6.36 % 6.34 %
Summary of Future Minimum Payments	As of December 31, 2022, future minimum payments during the next five years and thereafter are as follows (amounts in thousands): Fiscal Year Operating Finance 2023 $ 7,461 $ 3,751 2024 8,892 5,131 2025 9,104 5,272 2026 9,039 5,417 2027 9,135 5,565 Thereafter 46,370 28,065 Total 90,001 53,201 Less present value discount ( 23,963 ) ( 13,823 ) Lease liabilities $ 66,038 $ 39,378

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Schedule of Future Minimum Purchase Commitments	As of December 31, 2022, future minimum purchase commitments in aggregate during the next five years and thereafter are as follows (amounts in thousands): Fiscal Year Minimum Purchase Commitments 2023 $ 2,775 2024 3,150 2025 2,358 2026 2,105 2027 1,418 Thereafter — Total $ 11,806

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2022
Stockholders' Equity Note [Abstract]
Schedule of Stock Option Activity	Stock option activity under the Plans, including the EPA Program discussed below is as follows: Number of Weighted Weighted Intrinsic value Balance as of December 31, 2021 (1) 53,078 $ 7.74 6.78 Granted (2) 2,100 23.04 Cancelled and forfeited (3) ( 1,222 ) 16.66 Exercised ( 3,832 ) 1.39 Balance as of December 31, 2022 50,124 $ 8.65 6.05 $ 129,209 Vested and expected to vest as of December 31, 2022 (4) 40,549 $ 5.25 5.36 $ 129,209 Vested and exercisable as of December 31, 2022 31,042 $ 1.73 4.44 $ 122,355 (1) This includes 14.7 million options granted in December 2021 pursuant to the EPA Program. (2) All options granted during the year ended December 31, 2022, were granted pursuant to the EPA Program. (3) This includes 0.8 million options forfeited from the EPA program. (4) This includes 6.4 million options granted pursuant to the EPA Program that are currently expected to vest. None of the options granted pursuant to the EPA Program were vested and exercisable as of December 31, 2022 .
Schedule of Additional Information Regarding Options Outstanding	Additional information regarding options outstanding as of December 31, 2022, is as follows: Range of Exercise Price per Share Number of Options Outstanding Weighted Average Exercise Price Weighted Average Remaining Contractual Life (Years) $ 0.64 2,414 $ 0.64 $ 0.32 $ 1.05 - $ 1.35 19,107 $ 1.29 $ 3.85 $ 2.38 10,112 $ 2.38 $ 6.56 $ 6.23 2,533 $ 6.23 $ 7.68 23.04 15,958 $ 23.04 $ 8.96 50,124 $ 8.65 $ 6.05
Schedule of Weighted Average Assumptions Used Inputs to Monte Carlo Simulation and Black-Scholes OPM	The following weighted average assumptions were used as inputs to the Monte Carlo simulation in determining the estimated grant-date fair value of the Company’s stock options for the year ended December 31, 2022: Year Ended December 31, 2022 2021 Volatility 98.69 % 112.49 % Risk-free interest rate 3.52 % 1.44 % Expected dividend — — Cost of equity 14.62 % 11.66 % Weighted average fair value at grant date $ 4.93 $ 20.58 All options granted during the years ended December 31, 2022 and December 31, 2021, were granted pursuant the EPA Program and were valued using a Monte Carlo simulation. The Monte Carlo simulation used in the valuation of the options required the Company to make assumptions and judgements about the variables used in the calculation including the expected term, volatility of the Company's common stock and cost of equity. The Company estimated expected term based on the midpoint between the time of vesting and the remaining time to expiration of the option. For options granted in December 2021, given the limited market trading history of the Company's common stock, volatility is based on a weighted blend of (i) the average volatility of peer companies within the automotive and energy storage industries multiplied by a ratio of the Company's volatility based on available stock price data as compared to the average volatility of the Company's peers over the same period and (ii) our implied volatility from exchange traded options. For options granted in December 2022, volatility is based on a blend of (i) the Company’s historical volatility from daily closing stock prices given increased trading history and (ii) the Company’s implied volatility from exchange traded options. Cost of equity is calculated using (i) risk-free rate, (ii) average peer group market beta and (iii) the market-risk premium. The following weighted average assumptions were used as inputs to the Black-Scholes Option Pricing Model in determining the estimated grant-date fair value of the Company’s stock options for the years ended December 31, 2020: Year Ended December 31, 2020 Volatility 70.00 % Risk-free interest rate 0.39 % Expected term (in years) 6.08 Expected dividend — Weighted average fair value at grant date $ 2.67 For options granted with only service conditions, the Company uses the simplified calculation of the expected life for the valuation of options, which takes into consideration the grant’s contractual life and vesting period and assumes that all options will be exercised between the vesting date and the contractual term of the option. Given the lack of a public market for the Company’s common stock prior to the Business Combination and the Company's minimal history as a public company subsequent to the Business Combination, the estimate for volatility is based on an average of the historical volatilities of the common stock of several entities with characteristics similar to those of the Company. Since these comparable companies operate in the same industry segment, the Company expects that it would share similar characteristics, such as risks profiles, volatility, capital intensity, clientele, and market growth patterns and drivers. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods corresponding with the expected life of the option. EPA
Summary of Vesting Tranches	Each of the five Tranches vest only if the Company achieves one of the business milestones (in addition to the business milestones already achieved in a prior Tranche) and achieves the applicable stock price target on or after the business milestone is achieved, within 10 years of the initial grants. Additionally, in order to vest in any Tranche, Participants generally must continue to provide service through the date of vesting in the same position, or a similar or higher role, as when the EPA Program awards are granted. Tranche Business Milestone Requirement Stock Price Target 1 Achievement of 1 business milestone $ 60 2 Achievement of 2 business milestones (inclusive of the business milestone applicable to Tranche 1) $ 120 3 Achievement of 3 business milestones (inclusive of the business milestone applicable to Tranche 2) $ 180 4 Achievement of 4 business milestones (inclusive of the business milestone applicable to Tranche 3) $ 240 5 Achievement of 5 business milestones (inclusive of the business milestone applicable to Tranche 4) $ 300
Schedule of Restricted Stock Unit Activity	Restricted stock unit activity under the Plans are as follows: Number of Weighted Balance as of December 31, 2020 13,913 $ 8.94 Granted 2,082 30.28 Vested ( 5,027 ) 6.00 Forfeited ( 414 ) 10.97 Balance as of December 31, 2021 10,555 14.48 Granted 12,466 13.13 Vested ( 5,297 ) 12.75 Forfeited ( 1,161 ) 17.18 Balance as of December 31, 2022 16,563 13.79
Schedule of Stock-based Compensation Expense	Total stock-based compensation expense recognized in the accompanying Consolidated Statements of Operations and Comprehensive Loss for all equity awards is as follows (amounts in thousands): Year Ended December 31, 2022 2021 2020 Research and development $ 62,892 $ 29,653 $ 9,889 General and administrative 64,218 22,522 7,135 Total stock-based compensation expense $ 127,110 $ 52,175 $ 17,024

Earnings (Loss) Per Share (Tabl

Earnings (Loss) Per Share (Tables)	12 Months Ended
	Dec. 31, 2022
Schedule Of Earnings Per Share Basic And Diluted [Abstract]
Summary of Basic and Diluted Loss per Share of Common Stock	The following table sets forth the computation of basic and diluted loss per Class A Common Stock and Class B Common Stock (amounts in thousands, except per share amounts): Year Ended December 31, 2022 2021 2020 Numerator: Net loss attributable to common stockholders - Basic $ ( 411,907 ) $ ( 45,966 ) $ ( 1,681,777 ) Less: Change in fair value of assumed common stock warrant liabilities — ( 168,674 ) — Net loss attributable to common stockholders - Diluted $ ( 411,907 ) $ ( 214,640 ) $ ( 1,681,777 ) Denominator: Weighted average Class A and Class B Common Stock outstanding- Basic 432,973 404,259 252,144 Effect of dilutive securities — 5,250 — Weighted average Class A and Class B Common Stock outstanding - Diluted 432,973 409,509 252,144 Net loss per share attributable to Class A and Class B Common stockholders - Basic $ ( 0.95 ) $ ( 0.11 ) $ ( 6.67 ) Net loss per share attributable to Class A and Class B Common stockholders - Diluted $ ( 0.95 ) $ ( 0.52 ) $ ( 6.67 )
Summary of Potential Common Stock Outstanding Excluded from Computation of Diluted Net Loss Per Share	The following table presents the potential common stock outstanding that was excluded from the computation of diluted net loss per share of common stock as of the periods presented because including them would have been antidilutive (amounts in thousands): Year Ended December 31, 2022 2021 2020 Warrants — — 18,150 Options outstanding 50,124 53,078 55,316 Restricted stock units 16,563 10,555 13,913 VGA contingent purchase commitment (1) — — 15,221 Total 66,687 63,633 102,600 (1) This refers to VGA’s commitment to purchase 15.2 million shares of Class A Common Stock for $ 100.0 million subject to certain conditions including the achievement of a specified technical milestone by March 31, 2021. All shares were issued subsequent to the fulfillment of these conditions.

Joint Venture and Redeemable _2

Joint Venture and Redeemable Non-Controlling Interest (Tables)	12 Months Ended
	Dec. 31, 2022
Joint Venture And Non Controlling Interest [Abstract]
Schedule of Change in Redeemable Non-Controlling Interest	The following table sets forth the change in redeemable non-controlling interest for years ended December 31, 2022, 2021 and 2020 (amounts in thousands): Redeemable Non-Controlling Balance as of December 31, 2019 $ 1,710 Net loss attributable to redeemable non-controlling interest in QSV ( 6 ) Balance as of December 31, 2020 $ 1,704 Net loss attributable to redeemable non-controlling interest in QSV ( 11 ) Balance as of December 31, 2021 $ 1,693 Net income attributable to redeemable non-controlling interest in QSV 11 Balance as of December 31, 2022 $ 1,704

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Schedule of Reconciliation of Effective Income Tax Rate	A reconciliation from U.S. statutory rate of 21 % to the effective rate is as follows: Year Ended December 31, 2022 2021 2020 Federal Statutory rate 21.0 % 21.0 % 21.0 % State tax expense 7.0 % 7.1 % 0.0 % Stock-based compensation 1.7 % 349.5 % 0.0 % Change in fair value of assumed common stock warrant liabilities 0.0 % 103.1 % ( 7.3 %) Research and development tax credit 2.7 % 41.5 % 0.2 % Permanent tax items ( 0.1 %) ( 7.1 %) ( 0.2 %) State rate differential - change in apportionment 0.0 % 4.4 % ( 0.1 %) Prior year deferred true-up 4.6 % 2.5 % 0.1 % Change in fair value of Series F tranche liabilities 0.0 % 0.0 % ( 12.5 %) Sec. 162(m) wage limitation ( 2.2 %) ( 113.9 %) ( 0.1 %) Change to valuation allowance ( 34.7 %) ( 408.1 %) ( 1.1 %) Effective tax rate 0.0 % 0.0 % 0.0 %
Components of Net Deferred Tax Assets	Significant components of the Company’s net deferred tax assets as of December 31, 2022 and 2021, are as follows (amounts in thousands): Year Ended December 31, 2022 2021 Deferred tax assets: Net operating losses $ 336,617 $ 257,426 Tax credits 58,476 35,149 Accruals and stock-based compensation 28,152 10,479 Lease liability 30,571 20,234 Section 174 capitalized research & development 45,369 — Intangibles — 685 Gross deferred tax assets 499,185 323,973 Valuation allowance ( 438,212 ) ( 293,211 ) Total deferred tax assets $ 60,973 $ 30,762 Deferred tax liabilities: Right of use assets $ ( 24,450 ) $ ( 18,999 ) Intangibles ( 561 ) — Fixed assets ( 35,962 ) ( 11,763 ) Total deferred tax liabilities ( 60,973 ) ( 30,762 ) Total net deferred tax assets $ — $ —
Reconciliation of Beginning and Ending Balances of Valuation Allowance	A reconciliation of the beginning and ending balances of the valuation allowance is as follows (amounts in thousands): Year Ended December 31, 2022 2021 2020 Beginning of the year $ ( 293,211 ) $ ( 105,781 ) $ ( 85,677 ) Increase ( 145,001 ) ( 187,430 ) ( 20,104 ) End of the year $ ( 438,212 ) $ ( 293,211 ) $ ( 105,781 )
Reconciliation of Beginning and Ending Balances of Unrecognized Tax Benefits	A reconciliation of the beginning and ending balances of unrecognized tax benefits is as follows (amounts in thousands): Year Ended December 31, 2022 2021 2020 Beginning of the year $ 32,172 $ 6,575 $ 7,076 Increase—current year positions 12,388 20,633 1,553 Decrease—current year positions ( 5,056 ) — — Increase—prior year positions 13,298 5,056 193 Decrease—prior year positions — ( 92 ) ( 2,247 ) End of the year $ 52,802 $ 32,172 $ 6,575

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Additional Information (Details)		6 Months Ended	12 Months Ended
	Sep. 02, 2020 $ / shares	Jun. 30, 2021 shares	Dec. 31, 2022 USD ($) Segment $ / shares shares	Dec. 31, 2021 USD ($) $ / shares shares	Dec. 31, 2020 USD ($) shares	Dec. 31, 2019 USD ($)	Sep. 30, 2018 Agreement
Summary Of Significant Accounting Policies [Line Items]
Goodwill or other intangible assets | $			$ 0
Number of operating agreements of joint venture parties | Agreement							2
Restricted cash | $			17,500,000	$ 17,500,000
Cancellation charges incurred related to process and equipment development | $			2,800,000
Impairment of long-lived assets | $			$ 13,695,000
Number of reportable segment | Segment			1
Number of operating segment | Segment			1
Redeemable non-controlling interest | $			$ 1,704,000	$ 1,693,000	$ 1,704,000	$ 1,710,000
Legacy Quantum Scape
Summary Of Significant Accounting Policies [Line Items]
Business combination, effective date of acquisition			Nov. 25, 2020
Business combination, date of acquisition agreement			Sep. 02, 2020
Business combination exchange ratio	4.02175014920
Public Warrants
Summary Of Significant Accounting Policies [Line Items]
Warrant exercisable number of shares | shares			1
Warrants sold | shares			11,499,989
Warrant exercise price | $ / shares			$ 11.50
Warrants outstanding | shares				0	11,499,989
Minimum percentage of class A stockholders required for settlement of shares			50%
Private Placement Warrants
Summary Of Significant Accounting Policies [Line Items]
Warrants sold | shares			6,650,000
Warrant issued in connection with the closing of business combination | shares			75,000
Warrants outstanding | shares				0	6,650,000
Class A Common Stock
Summary Of Significant Accounting Policies [Line Items]
Common stock, par value | $ / shares			$ 0.0001	$ 0.0001
Number of shares purchased | shares			510,993
Class A Common Stock | Legacy Quantum Scape
Summary Of Significant Accounting Policies [Line Items]
Common stock, par value | $ / shares	$ 0.0001
Class A Common Stock | 2020 Equity Employee Stock Purchase Plan
Summary Of Significant Accounting Policies [Line Items]
Common stock reserved for future issuance | shares			11,300,000
Class A Common Stock | 2020 Equity Employee Stock Purchase Plan | Maximum
Summary Of Significant Accounting Policies [Line Items]
Purchase of common stock | shares		1,000
Class B Common Stock
Summary Of Significant Accounting Policies [Line Items]
Common stock, par value | $ / shares			$ 0.0001	$ 0.0001
Class B Common Stock | Legacy Quantum Scape
Summary Of Significant Accounting Policies [Line Items]
Common stock, par value | $ / shares	$ 0.0001
US Government Money Market Fund and Marketable Securities
Summary Of Significant Accounting Policies [Line Items]
Investment securities | $			$ 107,400,000	$ 227,800,000
U.S. Government and Agency Securities
Summary Of Significant Accounting Policies [Line Items]
Investment securities | $			$ 610,500,000	$ 722,300,000
JVA
Summary Of Significant Accounting Policies [Line Items]
Percentage of joint venture holders voting interest			21.50%	19.80%
Contribution in exchange for equity interests | $			$ 1,700,000
Equity interests percentage			50%
Redeemable non-controlling interest | $			$ 1,700,000

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Summary of Property and Equipment and Their Estimated Useful Lives (Details)	12 Months Ended
	Dec. 31, 2022
Computer Equipment, Hardware, and Software | Minimum
Summary Of Significant Accounting Policies [Line Items]
Estimated useful lives of assets	3 years
Computer Equipment, Hardware, and Software | Maximum
Summary Of Significant Accounting Policies [Line Items]
Estimated useful lives of assets	5 years
Furniture and Fixtures | Minimum
Summary Of Significant Accounting Policies [Line Items]
Estimated useful lives of assets	7 years
Furniture and Fixtures | Maximum
Summary Of Significant Accounting Policies [Line Items]
Estimated useful lives of assets	10 years
Machinery and Equipment | Minimum
Summary Of Significant Accounting Policies [Line Items]
Estimated useful lives of assets	3 years
Machinery and Equipment | Maximum
Summary Of Significant Accounting Policies [Line Items]
Estimated useful lives of assets	10 years
Leasehold Improvements
Summary Of Significant Accounting Policies [Line Items]
Estimated useful lives of assets	Shorter of the lease term (including estimated renewals) or the estimated useful lives of the improvements

Recent Accounting Pronounceme_2

Recent Accounting Pronouncements - Additional Information (Details)	Dec. 31, 2022
ASU 2020-06
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]
Change in accounting principle, accounting standards update, adopted	true
Change in accounting principle, accounting standards update, adoption date	Jan. 01, 2022
Change in accounting principle, accounting standards update, immaterial effect	true
ASU 2021-10
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]
Change in accounting principle, accounting standards update, adopted	true
Change in accounting principle, accounting standards update, adoption date	Jan. 01, 2022
Change in accounting principle, accounting standards update, immaterial effect	true
ASU 2022-06
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]
Change in accounting principle, accounting standards update, adopted	true
Change in accounting principle, accounting standards update, adoption date	Dec. 31, 2022
Change in accounting principle, accounting standards update, immaterial effect	true

Business Combination - Addition

Business Combination - Additional Information (Details)		12 Months Ended
	Sep. 02, 2020 $ / shares	Dec. 31, 2022 $ / shares shares	Dec. 31, 2021 $ / shares shares
Business Combination [Line Items]
Common stock, authorized | shares		1,250,000,000	1,250,000,000
Preferred stock, authorized | shares		100,000,000	100,000,000
Number of votes each shareholder entitled		The holder of each share of Class A Common Stock is entitled to one vote, and the holder of each share of Class B Common Stock is entitled to ten votes.
Legacy Quantum Scape
Business Combination [Line Items]
Business combination, effective date of acquisition		Nov. 25, 2020
Business combination, date of acquisition agreement		Sep. 02, 2020
Business combination exchange ratio	4.02175014920
Class A Common Stock
Business Combination [Line Items]
Common stock, par value | $ / shares		$ 0.0001	$ 0.0001
Common stock, authorized | shares		1,000,000,000	1,000,000,000
Class A Common Stock | Legacy Quantum Scape
Business Combination [Line Items]
Common stock, par value | $ / shares	$ 0.0001
Class B Common Stock
Business Combination [Line Items]
Common stock, par value | $ / shares		$ 0.0001	$ 0.0001
Common stock, authorized | shares		250,000,000	250,000,000
Class B Common Stock | Legacy Quantum Scape
Business Combination [Line Items]
Common stock, par value | $ / shares	$ 0.0001

Business Combination - Reconcil

Business Combination - Reconciliation of Elements of Business Combination to Consolidated Statement of Cash Flows and Consolidated Statement of Redeemable Non-Controlling Interest and Stockholders' Equity (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Business Combination [Line Items]
Proceeds from issuance of common stock, net of issuance costs paid	$ 462,926
Net cash contributions from Business Combination	$ (1,016)	$ 676,863

Business Combination - Schedule

Business Combination - Schedule of Number of Shares of Common Stock Issued Immediately Following Consummation of Business Combination (Details) - shares	Dec. 31, 2022	Dec. 31, 2021
Class A Common Stock
Business Combination [Line Items]
Common stock, outstanding	358,505,000	332,869,000
Common stock, issued	358,505,000	332,869,000
Class B Common Stock
Business Combination [Line Items]
Common stock, outstanding	79,454,000	95,450,000
Common stock, issued	79,454,000	95,450,000

Business Combination - Schedu_2

Business Combination - Schedule of Number of Shares of Common Stock Issued Immediately Following Consummation of Business Combination (Parenthetical) (Details) - shares	Dec. 31, 2022	Dec. 31, 2021
Class A Common Stock
Business Combination [Line Items]
Common stock, outstanding	358,505,000	332,869,000
Class B Common Stock
Business Combination [Line Items]
Common stock, outstanding	79,454,000	95,450,000

Fair Value Measurement - Summar

Fair Value Measurement - Summary of Financial Assets and Liabilities Subject to Fair Value Measurements on Recurring Basis (Details) - Recurring - USD ($) $ in Thousands		Dec. 31, 2022	Dec. 31, 2021
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total fair value assets		$ 1,010,778	$ 1,440,920
Money Market Funds
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total fair value assets	[1]	107,439	227,826
Commercial Paper
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total fair value assets	[2]	104,231	233,400
U.S. Government and Agency Securities
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total fair value assets	[2]	610,450	722,310
Corporate Notes and Bonds
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total fair value assets	[2]	188,658	257,384
Level 1
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total fair value assets		107,439	227,826
Level 1 | Money Market Funds
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total fair value assets	[1]	107,439	227,826
Level 2
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total fair value assets		903,339	1,213,094
Level 2 | Commercial Paper
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total fair value assets	[2]	104,231	233,400
Level 2 | U.S. Government and Agency Securities
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total fair value assets	[2]	610,450	722,310
Level 2 | Corporate Notes and Bonds
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total fair value assets	[2]	$ 188,658	$ 257,384
[1] Money market funds are included in cash and cash equivalents on the Consolidated Balance Sheets. Marketable securities consist of commercial paper, U.S. government and agency securities, corporate notes and bonds. As of December 31, 2022 and 2021 , marketable securities with original maturities of three months or less of $ 77.0 million and $ 86.1 million, respectively, are included in cash and cash equivalents on the Consolidated Balance Sheets.

Fair Value Measurement - Summ_2

Fair Value Measurement - Summary of Financial Assets and Liabilities Subject to Fair Value Measurements on Recurring Basis (Parenthetical) (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Fair Value Disclosures [Abstract]
Marketable securities	$ 77	$ 86.1

Fair Value Measurement - Summ_3

Fair Value Measurement - Summary of Major Security Type Assets That Measured at Fair Value on Recurring Basis (Details) - Recurring - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Schedule of Available for Sale Securities [Line Items]
Amortized Cost	$ 1,028,651	$ 1,445,128
Gross Unrealized Gain	24
Gross Unrealized Loss	(17,897)	(4,208)
Fair Value	1,010,778	1,440,920
Level 1 | Money Market Funds
Schedule of Available for Sale Securities [Line Items]
Amortized Cost	107,439	227,826
Fair Value	107,439	227,826
Level 2 | Commercial Paper
Schedule of Available for Sale Securities [Line Items]
Amortized Cost	104,231	233,400
Fair Value	104,231	233,400
Level 2 | U.S. Government and Agency Securities
Schedule of Available for Sale Securities [Line Items]
Amortized Cost	620,660	724,554
Gross Unrealized Gain	24
Gross Unrealized Loss	(10,234)	(2,244)
Fair Value	610,450	722,310
Level 2 | Corporate Notes and Bonds
Schedule of Available for Sale Securities [Line Items]
Amortized Cost	196,321	259,348
Gross Unrealized Loss	(7,663)	(1,964)
Fair Value	$ 188,658	$ 257,384

Fair Value Measurement - Summ_4

Fair Value Measurement - Summary of Gross Unrealized Losses and Fair Value for Marketable Securities (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Debt Securities, Available-for-Sale [Line Items]
Gross unrealized loss less than 12 consecutive months	$ (782)	$ (4,203)
Fair value less than 12 consecutive months	249,632	957,702
Gross unrealized loss 12 consecutive months or longer	(17,115)	(5)
Fair value 12 consecutive months or longer	506,590	17,011
Total gross unrealized loss	(17,897)	(4,208)
Total fair value	756,222	974,713
U.S. Government and Agency Securities
Debt Securities, Available-for-Sale [Line Items]
Gross unrealized loss less than 12 consecutive months	(521)	(2,239)
Fair value less than 12 consecutive months	231,047	700,318
Gross unrealized loss 12 consecutive months or longer	(9,713)	(5)
Fair value 12 consecutive months or longer	336,517	17,011
Total gross unrealized loss	(10,234)	(2,244)
Total fair value	567,564	717,329
Corporate Notes and Bonds
Debt Securities, Available-for-Sale [Line Items]
Gross unrealized loss less than 12 consecutive months	(261)	(1,964)
Fair value less than 12 consecutive months	18,585	257,384
Gross unrealized loss 12 consecutive months or longer	(7,402)
Fair value 12 consecutive months or longer	170,073
Total gross unrealized loss	(7,663)	(1,964)
Total fair value	$ 188,658	$ 257,384

Fair Value Measurement - Additi

Fair Value Measurement - Additional Information (Details)			1 Months Ended			12 Months Ended
	Mar. 31, 2021 USD ($) shares	Dec. 01, 2020 USD ($) shares	Sep. 30, 2020 USD ($) Tranche $ / shares shares	Aug. 31, 2020 USD ($) $ / shares shares	May 31, 2020 USD ($) Tranche $ / shares shares	Dec. 31, 2022 USD ($) Security shares	Dec. 31, 2021 USD ($) Security shares	Dec. 31, 2020 USD ($)	Nov. 25, 2020 $ / shares
Class of Stock [Line Items]
Financial liabilities subject to fair value measurements on recurring basis						$ 0	$ 0
Number of marketable securities in an unrealized loss position | Security						95	118
Proceeds from sale of available-for sale marketable securities						$ 15,200,000	$ 225,100,000	$ 14,000,000
Allowance for credit losses						$ 0	$ 0
Preferred stock, shares issued | shares						0	0
Series F Convertible Preferred Stock
Class of Stock [Line Items]
Warrant exercise price | $ / shares			$ 26.4218	$ 26.4218	$ 26.4218				$ 26.42
Proceeds from issuance of convertible preferred stock			$ 200,000,000	$ 188,000,000	$ 200,000,000
Preferred stock, shares issued | shares			7,569,508	7,115,335	7,569,508
Number of funded tranches | Tranche			2		2
Adjusted exchange ratio of warrants | $ / shares									$ 23.50
Tranche One | Series F Convertible Preferred Stock
Class of Stock [Line Items]
Proceeds from issuance of convertible preferred stock		$ 100,000,000
Preferred stock, shares issued | shares		3,784,754
Tranche Two | Series F Convertible Preferred Stock
Class of Stock [Line Items]
Proceeds from issuance of convertible preferred stock	$ 100,000,000
Preferred stock, shares issued | shares	3,784,754
Tranche Three | Series F Convertible Preferred Stock
Class of Stock [Line Items]
Proceeds from issuance of convertible preferred stock				$ 94,000,000
Tranche Four | Series F Convertible Preferred Stock
Class of Stock [Line Items]
Proceeds from issuance of convertible preferred stock				$ 94,000,000

Fair Value Measurement - Summ_5

Fair Value Measurement - Summary of Estimated Amortized Cost and Fair Value of Available-for-Sale Securities by Contractual Maturity (Details) $ in Thousands	Dec. 31, 2022 USD ($)
Investments, Debt and Equity Securities [Abstract]
Amortized Cost, Due within one year	$ 803,011
Amortized Cost, Due after one year and through five years	225,640
Total Amortized Cost	1,028,651
Fair Value, Due within one year	797,053
Fair Value, Due after one year and through five years	213,725
Total Fair Value	$ 1,010,778

Fair Value Measurement - Schedu

Fair Value Measurement - Schedule of Reconciliation of Warrants and Tranche Liabilities Measured and Recorded at Fair Value on Recurring Basis Using Significant Unobservable Inputs (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2020
Fair Value Liabilities Measured on Recurring Basis Unobservable Input Reconciliation [Line Items]
Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Other Nonoperating Income (Expense)
Series F Convertible Preferred Stock
Fair Value Liabilities Measured on Recurring Basis Unobservable Input Reconciliation [Line Items]
Re-measurement loss included in interest expense		$ 999,865
Issuance of Legacy QuantumScape Series F Preferred Stock - tranche shares 3 and 4		(484,471)
Reclassification to additional paid-in capital upon Closing of the Business Combination - tranche shares 1 and 2		$ (515,394)

Balance Sheet Components - Sche

Balance Sheet Components - Schedule of Property and Equipment (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 365,959	$ 209,421
Accumulated depreciation and amortization	(70,025)	(43,238)
Property and equipment, net	295,934	166,183
Computer Equipment, Hardware, and Software
Property Plant And Equipment [Line Items]
Property and equipment, gross	6,784	2,740
Furniture and Fixtures
Property Plant And Equipment [Line Items]
Property and equipment, gross	57,771	15,116
Leasehold Improvements
Property Plant And Equipment [Line Items]
Property and equipment, gross	72,201	23,192
Machinery and Equipment
Property Plant And Equipment [Line Items]
Property and equipment, gross	120,618	66,953
Construction in Progress
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 108,585	$ 101,420

Balance Sheet Components - Addi

Balance Sheet Components - Additional Information (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Property, Plant and Equipment [Abstract]
Depreciation and amortization expense related to property and equipment	$ 27.4	$ 11.7	$ 7.5

Balance Sheet Components - Sc_2

Balance Sheet Components - Schedule of Accrued Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Accrued Liabilities, Current [Abstract]
Accrued property and equipment	$ 3,152	$ 1,815
Accrued facilities expense	1,106	1,637
Other	3,219	2,626
Accrued liabilities	$ 7,477	$ 6,078

Balance Sheet Components - Sc_3

Balance Sheet Components - Schedule of Other Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Balance Sheet Related Disclosures [Abstract]
Long-term Advance Payments	$ 2,615	$ 315
Asset retirement obligation	5,873
Other liabilities	$ 8,488	$ 315

Leases - Additional Information

Leases - Additional Information (Details)	1 Months Ended			12 Months Ended
	Nov. 30, 2021 SquareFeet	Jun. 30, 2021	Apr. 30, 2021 ft² RenewalOption	Dec. 31, 2022
Lessee Lease Description [Line Items]
Operating lease expiration, year				2032
Operating lease extension expiration, month and year	2032-09	2032-09	2032-09
Operating lease, renewal term		5 years
Area of rentable space lease	222,000		197,000
Finance lease, existence of option to extend	true		true
Finance lease, option to extend	10-year
Finance lease, renewal term			5 years
Number of finance lease renewal options			2
Lessee, operating lease, lease not yet commenced, description				The November 2021 leases commenced in November 2021, January 2022, and April 2022 and were classified as operating leases. The additional 10-year extension period has not been included in the calculation of the lease liability and right-of-use asset at the lease inception as the exercise of the option was not reasonably certain.

Leases - Summary of Lease Relat

Leases - Summary of Lease Related Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Finance lease costs:
Amortization of right-of-use assets- finance lease	$ 2,873	$ 1,915
Interest on lease liabilities	2,399	1,419
Operating lease costs	9,082	3,016	$ 2,143
Variable lease costs	2,330	530	409
Total lease expense	$ 16,684	$ 6,880	$ 2,552

Leases - Summary of Supplementa

Leases - Summary of Supplemental Cash Flow Information Related to Leases (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Leases [Abstract]
Operating outgoing cash flows - finance lease	$ 1,610	$ 330
Financing outgoing cash flows - finance lease	809	73
Financing (incoming) cash flows - finance lease		(5,580)
Operating outgoing cash flows - operating lease	4,673	2,711	$ 1,994
Right-of-use assets obtained in exchange for new finance lease liabilities		32,802
Right-of-use assets obtained in exchange for new operating lease liabilities	$ 28,845	$ 26,778

Leases - Summary of Additional

Leases - Summary of Additional Information for Lease (Details)	Dec. 31, 2022	Dec. 31, 2021
Finance lease
Weighted-average remaining lease term - finance lease (in years)	9 years 9 months 18 days	10 years 9 months 18 days
Weighted-average discount rate - finance lease	6.06%	6.06%
Operating lease
Weighted-average remaining lease term - operating lease (in years)	9 years 7 months 6 days	10 years 8 months 12 days
Weighted-average discount rate - operating lease	6.36%	6.34%

Leases - Summary of Future Mini

Leases - Summary of Future Minimum Payments (Details) $ in Thousands	Dec. 31, 2022 USD ($)
Leases [Abstract]
2023	$ 7,461
2024	8,892
2025	9,104
2026	9,039
2027	9,135
Thereafter	46,370
Total	90,001
Less present value discount	(23,963)
Lease liabilities	66,038
2023	3,751
2024	5,131
2025	5,272
2026	5,417
2027	5,565
Thereafter	28,065
Total	53,201
Less present value discount	(13,823)
Lease liabilities	$ 39,378

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Details)		1 Months Ended	12 Months Ended
	Jun. 07, 2022 Suit	Feb. 28, 2021 Suit OfficerDirector	Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Number of shareholder derivative suit filed | Suit	4	2
Number of officers and directors in shareholder derivative suit | OfficerDirector		11
Other commitments, description			The Company's minimum purchase commitments consist of non-cancellable agreements to purchase goods and services, primarily for materials, and licenses and hosting services, entered into in the ordinary course of business.

Commitments and Contingencies_2

Commitments and Contingencies - Schedule of Future Minimum Purchase Commitments (Details) $ in Thousands	Dec. 31, 2022 USD ($)
Commitments and Contingencies Disclosure [Abstract]
Minimum purchase commitments, 2023	$ 2,775
Minimum purchase commitments, 2024	3,150
Minimum purchase commitments, 2025	2,358
Minimum purchase commitments, 2026	2,105
Minimum purchase commitments, 2027	1,418
Minimum purchase commitments, Total	$ 11,806

Assumed Common Stock Warrants -

Assumed Common Stock Warrants - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Class Of Warrant Or Right [Line Items]
Change in fair value of assumed common stock warrant liabilities		$ 168,674	$ (581,863)
Public Warrants
Class Of Warrant Or Right [Line Items]
Warrants sold	11,499,989
Warrants exercise price per share	$ 11.50
Warrant exercisable number of shares	1
Private Placement Warrants
Class Of Warrant Or Right [Line Items]
Warrants sold	6,650,000
Warrant issued in connection with the closing of business combination	75,000

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Details)		1 Months Ended		3 Months Ended	12 Months Ended
		Dec. 31, 2021 Tranche $ / shares shares	Mar. 31, 2021 USD ($) shares	Mar. 31, 2021 USD ($) shares	Dec. 31, 2022 USD ($) Tranche $ / shares shares	Dec. 31, 2021 USD ($) $ / shares shares	Dec. 31, 2020 USD ($) $ / shares	Sep. 02, 2020 $ / shares
Class of Stock [Line Items]
Shares authorized | shares		1,350,000,000			1,350,000,000	1,350,000,000
Common stock, authorized | shares		1,250,000,000			1,250,000,000	1,250,000,000
Preferred stock, authorized | shares		100,000,000			100,000,000	100,000,000
Common stock voting rights, description					The holder of each share of Class A Common Stock is entitled to one vote, and the holder of each share of Class B Common Stock is entitled to ten votes.
Proceeds from common stock						$ 462,926,000
Options vesting period					4 years
Weighted average fair value at grant date | $ / shares					$ 4.93	$ 20.58	$ 2.67
Granted stock option | shares	[1]				2,100,000
Stock-based compensation expense					$ 127,110,000	$ 52,175,000	$ 17,024,000
Fair value of restricted stock vested					65,500,000	198,000,000	0
Aggregate intrinsic value					42,000,000	$ 489,700,000	$ 3,500,000
Stock-based compensation unvested stock options not yet recognized					$ 6,400,000
Expected to be recognized estimated weighted average period					1 year 9 months 18 days
EPA
Class of Stock [Line Items]
Options vesting period					10 years
Granted stock option | shares						14,700,000
Number of Tranches Considered Probable | Tranche					2
Stock-based compensation expense					$ 49,400,000	$ 2,400,000
Expected to be recognized estimated weighted average period					2 years 8 months 12 days
Unrecognized compensation costs					$ 65,300,000
Number of tranches | Tranche		5			5
Business milestones description					The compensation committee of the Board selected the following eleven business milestones for the EPA Program, of which one milestone must be achieved for each tranche.•Delivery of an A-sample battery cell that meets specifications agreed upon with an automaker•The validation by an auto maker of a completed B-sample battery cell (a B-sample battery cell is a functional, complete battery cell prototype produced from our pre-pilot or sample production line)•Delivery of at least 1-gigawatt hour (GWh) of battery cells to a single customer•Delivery of at least 3-gigawatt hour (GWh) of battery cells to each of three or more customers, with at least one of such customer being an auto maker•$5 billion in GAAP revenue over a period of trailing four quarters•$10 billion in GAAP revenue over a period of trailing four quarters•Total cumulative battery cell production of 500 GWh•Total cumulative battery cell production of 1,000 GWh•Adjusted EBITDA margin of at least 25% over four consecutive quarters•10% of worldwide market share in automotive battery cells (excluding China)•20% of worldwide market share in automotive battery cells (excluding China)
Stock price targets description					To meet the stock price targets, the stock price must be sustained and not merely momentarily achieved. Except in the case of a change in control, the Company’s stock price for the purposes of assessing the stock price target will be the 120-day trailing average closing price (based on trading days), but a stock price target will not be achieved unless the trailing average closing price of the last 30 trading days of such 120-trading day period also meets or exceeds the applicable stock price target. For a stock price target for any given Tranche to be achieved, the last day of the 120-day measurement period must occur on or after the date that the requisite number of business milestones have been achieved for such Tranche.
EPA | Tranche 1
Class of Stock [Line Items]
Stock price targets					$ 60
EPA | Tranche 2
Class of Stock [Line Items]
Stock price targets					120
EPA | Tranche 3
Class of Stock [Line Items]
Stock price targets					180
EPA | Tranche 4
Class of Stock [Line Items]
Stock price targets					240
EPA | Tranche 5
Class of Stock [Line Items]
Stock price targets					300
EPA | Milestones Currently, Not Probable of Achievement
Class of Stock [Line Items]
Unrecognized compensation costs					$ 178,400,000
Restricted Stock Unit
Class of Stock [Line Items]
Expected to be recognized estimated weighted average period					2 years 10 months 24 days
Unrecognized compensation costs					$ 207,900,000
2020 Equity Incentive Award Plan
Class of Stock [Line Items]
Options is granted to stockholder, percentage					10%
Options vesting period					4 years
Options contractual terms					10 years
Minimum | 2020 Equity Incentive Award Plan
Class of Stock [Line Items]
Options granted price per share					100%
Options purchase or exercise price per share					110%
Class A Common Stock
Class of Stock [Line Items]
Common stock, authorized | shares		1,000,000,000			1,000,000,000	1,000,000,000
Common stock, par value | $ / shares		$ 0.0001			$ 0.0001	$ 0.0001
Stock issuance costs						$ 15,500,000
Common stock, issued | shares		332,869,000			358,505,000	332,869,000
Class A Common Stock | EPA
Class of Stock [Line Items]
Granted stock option | shares					2,100,000	14,700,000
Class A Common Stock | 2020 Equity Incentive Award Plan
Class of Stock [Line Items]
Common stock authorized for issuance | shares					62,915,959
Common Stock are reserved and available for future issuance | shares					33,806,148
Class A Common Stock | 2020 Equity Employee Stock Purchase Plan
Class of Stock [Line Items]
Common Stock are reserved and available for future issuance | shares					11,300,000
Class A Common Stock | Maximum | 2020 Equity Incentive Award Plan
Class of Stock [Line Items]
Common stock authorized for issuance | shares					69,846,580
Class A Common Stock | VGA
Class of Stock [Line Items]
Common stock, issued | shares			15,200,000	15,200,000
Proceeds from common stock				$ 100,000,000
Class A Common Stock | Legacy Quantum Scape
Class of Stock [Line Items]
Common stock, par value | $ / shares								$ 0.0001
Class A Common Stock | March 2021 Public Offering
Class of Stock [Line Items]
Stock issuance costs			$ 15,500,000
Common stock, issued | shares			11,960,000	11,960,000
Proceeds from common stock			$ 462,900,000
Class B Common Stock
Class of Stock [Line Items]
Common stock, authorized | shares		250,000,000			250,000,000	250,000,000
Common stock, par value | $ / shares		$ 0.0001			$ 0.0001	$ 0.0001
Common stock, issued | shares		95,450,000			79,454,000	95,450,000
Class B Common Stock | Legacy Quantum Scape
Class of Stock [Line Items]
Common stock, par value | $ / shares								$ 0.0001
[1] All options granted during the year ended December 31, 2022, were granted pursuant to the EPA Program.

Stockholders' Equity - Schedule

Stockholders' Equity - Schedule of Stock Option Activity (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands		12 Months Ended
		Dec. 31, 2022	Dec. 31, 2021	[1]
Class of Stock [Line Items]
Outstanding at the beginning of the period (in shares)	[1]	53,078
Granted (in shares)	[2]	2,100
Cancelled and forfeited (in shares)	[3]	(1,222)
Exercised (in shares)		(3,832)
Outstanding at the end of the period (in shares)		50,124	53,078
Vested and expected to vest at the end of the period (in shares)	[4]	40,549
Vested and exercisable at the end of the period (in shares)		31,042
Outstanding at the beginning of the period (in dollars per share)	[1]	$ 7.74
Granted (in dollars per share)	[2]	23.04
Cancelled and forfeited (in dollars per share)	[3]	16.66
Exercised (in dollars per share)		1.39
Outstanding at the end of the period (in dollars per share)		8.65	$ 7.74
Vested and expected to vest (in dollars per share)	[4]	5.25
Vested and exercisable (in dollars per share)		$ 1.73
Weighted Average Remaining Contractual Term (Years)		6 years 18 days	6 years 9 months 10 days
Weighted Average Remaining Contractual Term (Years), vested and expected to vest	[4]	5 years 4 months 9 days
Weighted Average Remaining Contractual Term (Years), vested and exercisable		4 years 5 months 8 days
Intrinsic value, balance at end of period		$ 129,209
Intrinsic value, vested and expected to vest at end of period	[4]	129,209
Intrinsic value, vested and exercisable at end of period		$ 122,355
[1] This includes 14.7 million options granted in December 2021 pursuant to the EPA Program. All options granted during the year ended December 31, 2022, were granted pursuant to the EPA Program. This includes 0.8 million options forfeited from the EPA program. This includes 6.4 million options granted pursuant to the EPA Program that are currently expected to vest. None of the options granted pursuant to the EPA Program were vested and exercisable as of December 31, 2022 .

Stockholders' Equity - Schedu_2

Stockholders' Equity - Schedule of Stock Option Activity (Parenthetical) (Details) - shares shares in Thousands		12 Months Ended
		Dec. 31, 2022	Dec. 31, 2021
Class of Stock [Line Items]
Granted stock option	[1]	2,100
Options forfeited	[2]	1,222
Vested and expected to vest at the end of the period (in shares)	[3]	40,549
EPA
Class of Stock [Line Items]
Granted stock option			14,700
Options forfeited		800
Vested and expected to vest at the end of the period (in shares)		6,400
[1] All options granted during the year ended December 31, 2022, were granted pursuant to the EPA Program. This includes 0.8 million options forfeited from the EPA program. This includes 6.4 million options granted pursuant to the EPA Program that are currently expected to vest. None of the options granted pursuant to the EPA Program were vested and exercisable as of December 31, 2022 .

Stockholders Equity - Schedule

Stockholders Equity - Schedule of Additional Information Regarding Options Outstanding (Details) - $ / shares shares in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	[1]
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]
Number of Options Outstanding	50,124
Weighted Average Exercise Price	$ 8.65	$ 7.74
Weighted Average Remaining Contractual Life (Years)	6 years 18 days
$0.64
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]
Range of Exercise Price per Share	$ 0.64
Number of Options Outstanding	2,414
Weighted Average Exercise Price	$ 0.64
Weighted Average Remaining Contractual Life (Years)	3 months 25 days
$1.05 - $1.35
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]
Number of Options Outstanding	19,107
Weighted Average Exercise Price	$ 1.29
Weighted Average Remaining Contractual Life (Years)	3 years 10 months 6 days
$1.05 - $1.35 | Minimum
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]
Range of Exercise Price per Share	$ 1.05
$1.05 - $1.35 | Maximum
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]
Range of Exercise Price per Share	1.35
$2.38
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]
Range of Exercise Price per Share	$ 2.38
Number of Options Outstanding	10,112
Weighted Average Exercise Price	$ 2.38
Weighted Average Remaining Contractual Life (Years)	6 years 6 months 21 days
$6.23
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]
Range of Exercise Price per Share	$ 6.23
Number of Options Outstanding	2,533
Weighted Average Exercise Price	$ 6.23
Weighted Average Remaining Contractual Life (Years)	7 years 8 months 4 days
23.04
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]
Range of Exercise Price per Share	$ 23.04
Number of Options Outstanding	15,958
Weighted Average Exercise Price	$ 23.04
Weighted Average Remaining Contractual Life (Years)	8 years 11 months 15 days
[1] This includes 14.7 million options granted in December 2021 pursuant to the EPA Program.

Stockholders' Equity - Schedu_3

Stockholders' Equity - Schedule of Weighted Average Assumptions Used Inputs to Monte Carlo Simulation and Black-Scholes OPM (Details) - $ / shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Share-Based Payment Arrangement [Abstract]
Volatility	98.69%	112.49%	70%
Risk-free interest rate	3.52%	1.44%	0.39%
Option term (in years)			6 years 29 days
Cost of equity	14.62%	11.66%
Weighted average fair value at grant date	$ 4.93	$ 20.58	$ 2.67

Stockholders' Equity - Summary

Stockholders' Equity - Summary of Vesting Tranches (Details) - EPA	12 Months Ended
	Dec. 31, 2022 USD ($)
Tranche 1
Class of Stock [Line Items]
Stock Price Target	$ 60
Tranche 2
Class of Stock [Line Items]
Stock Price Target	120
Tranche 3
Class of Stock [Line Items]
Stock Price Target	180
Tranche 4
Class of Stock [Line Items]
Stock Price Target	240
Tranche 5
Class of Stock [Line Items]
Stock Price Target	$ 300

Stockholders' Equity - Schedu_4

Stockholders' Equity - Schedule of Restricted Stock Unit Activity (Details) - Restricted Stock Unit - $ / shares shares in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Restricted Stock Units, Beginning Balance	10,555	13,913
Number of Restricted Stock Units, Granted	12,466	2,082
Number of Restricted Stock Units, Vested	(5,297)	(5,027)
Number of Restricted Stock Units, Forfeited	(1,161)	(414)
Number of Restricted Stock Units, Ending Balance	16,563	10,555
Weighted Average grant date fair value, Beginning Balance	$ 14.48	$ 8.94
Weighted Average grant date fair value, Granted	13.13	30.28
Weighted Average grant date fair value, Vested	12.75	6
Weighted Average grant date fair value, Forfeited	17.18	10.97
Weighted Average grant date fair value, Ending Balance	$ 13.79	$ 14.48

Stockholders Equity - Schedul_2

Stockholders Equity - Schedule of Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock-based compensation expense	$ 127,110	$ 52,175	$ 17,024
Research and Development
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock-based compensation expense	62,892	29,653	9,889
General and Administrative
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock-based compensation expense	$ 64,218	$ 22,522	$ 7,135

Earnings (Loss) Per Share - Sum

Earnings (Loss) Per Share - Summary of Basic and Diluted Loss per Share of Common Stock (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Numerator:
Net loss attributable to common stockholders - Basic	$ (411,907)	$ (45,966)	$ (1,681,777)
Less: Change in fair value of assumed common stock warrant liabilities		(168,674)	581,863
Net loss attributable to common stockholders - Diluted	$ (411,907)	$ (214,640)	$ (1,681,777)
Denominator:
Weighted average Class A and Class B Common Stock outstanding - Basic	432,973	404,259	252,144
Effect of dilutive securities		5,250
Weighted average Class A and Class B Common Stock outstanding - Diluted	432,973	409,509	252,144
Net loss per share attributable to Class A and Class B Common stockholders - Basic	$ (0.95)	$ (0.11)	$ (6.67)
Net loss per share attributable to Class A and Class B Common stockholders - Diluted	$ (0.95)	$ (0.52)	$ (6.67)
Common Class A and Class B Shares
Denominator:
Weighted average Class A and Class B Common Stock outstanding - Basic	432,973	404,259	252,144
Weighted average Class A and Class B Common Stock outstanding - Diluted	432,973	409,509	252,144
Net loss per share attributable to Class A and Class B Common stockholders - Basic	$ (0.95)	$ (0.11)	$ (6.67)
Net loss per share attributable to Class A and Class B Common stockholders - Diluted	$ (0.95)	$ (0.52)	$ (6.67)

Earnings (Loss) Per Share - S_2

Earnings (Loss) Per Share - Summary of Potential Common Stock Outstanding Excluded from Computation of Diluted Net Loss Per Share (Details) - shares shares in Thousands		12 Months Ended
		Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive		66,687	63,633	102,600
Warrants
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive				18,150
Options Outstanding
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive		50,124	53,078	55,316
Restricted Stock Unit
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive		16,563	10,555	13,913
VGA Contingent Purchase Commitment
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive	[1]			15,221
[1] This refers to VGA’s commitment to purchase 15.2 million shares of Class A Common Stock for $ 100.0 million subject to certain conditions including the achievement of a specified technical milestone by March 31, 2021. All shares were issued subsequent to the fulfillment of these conditions.

Earnings (Loss) Per Share - S_3

Earnings (Loss) Per Share - Summary of Potential Common Stock Outstanding Excluded from Computation of Diluted Net Loss Per Share (Parenthetical) (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2022
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Proceeds from issuance of common stock, net of issuance costs paid		$ 462,926
Class A Common Stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Common stock, issued		332,869,000	358,505,000
Class A Common Stock | VGA
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Common stock, issued	15,200,000
Proceeds from issuance of common stock, net of issuance costs paid	$ 100,000

Joint Venture and Redeemable _3

Joint Venture and Redeemable Non-Controlling Interest - Additional Information (Details) - USD ($) $ in Thousands	1 Months Ended		12 Months Ended
	Sep. 30, 2020	May 31, 2020	Dec. 31, 2020	Dec. 31, 2022	Dec. 31, 2021
Joint Venture And Non Controlling Interest [Line Items]
Cash and cash equivalents			$ 113,216	$ 235,393	$ 320,700
Proceeds from issuance of Series F preferred stock, net of issuance costs			$ 176,462
QSV
Joint Venture And Non Controlling Interest [Line Items]
Cash and cash equivalents				$ 3,395	$ 3,382
QSV | Series F Convertible Preferred Stock
Joint Venture And Non Controlling Interest [Line Items]
Proceeds from issuance of Series F preferred stock, net of issuance costs		$ 200,000
VWGoA | Series F Preferred Stock
Joint Venture And Non Controlling Interest [Line Items]
Proceed from Series F preferred stock financings and business combination	$ 134,000

Joint Venture and Redeemable _4

Joint Venture and Redeemable Non-Controlling Interest - Schedule of Change in Redeemable Non-Controlling Interest (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Joint Venture And Non Controlling Interest [Abstract]
Redeemable Non-Controlling, Beginning balance	$ 1,693	$ 1,704	$ 1,710
Net income (loss) attributable to redeemable non-controlling interest in QSV	11	(11)	(6)
Redeemable Non-Controlling, Ending balance	$ 1,704	$ 1,693	$ 1,704

Income Taxes - Additional Infor

Income Taxes - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Income Tax [Line Items]
Provision for income taxes	$ 0	$ 0	$ 0
Current income tax expense (benefit)	0	0	0
Deferred income tax expense (benefit)	$ 0	$ 0	$ 0
Federal Statutory rate	21%	21%	21%
Valuation allowance increase, amount	$ 145,001,000	$ 187,430,000	$ 20,104,000
Tax credit carryforward expiration beginning year	2031
Tax credit carryforward, description	The state tax credit carryforwards do not expire.
Unrecognized tax benefits	$ 52,802,000	32,172,000	6,575,000	$ 7,076,000
Interest or penalties related to unrecognized tax benefits.	$ 0	$ 0	$ 0
Income tax examination, description	The federal and state income tax returns are open under the statute of limitations subject to tax examinations for the tax years ended December 31, 2019 through December 31, 2021 and December 31, 2018 through December 31, 2021, respectively.
Research Tax Credit Carryforward | California Franchise Tax Board
Income Tax [Line Items]
Research and development credits	$ 48,500,000
Prior to 2018
Income Tax [Line Items]
Operating loss carryforwards, expire beginning date	2030
Federal
Income Tax [Line Items]
Operating loss carryforwards	$ 1,200,000,000
Federal | Research Tax Credit Carryforward
Income Tax [Line Items]
Research and development credits	68,400,000
Federal | Prior to 2018
Income Tax [Line Items]
Operating loss carryforwards	170,200,000
State
Income Tax [Line Items]
Operating loss carryforwards	1,190,000,000
State | Expire Beginning in 2030, If Not Utilized
Income Tax [Line Items]
Operating loss carryforwards	$ 1,030,000,000

Income Taxes - Schedule of Reco

Income Taxes - Schedule of Reconciliation of Effective Income Tax Rate (Details)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Federal Statutory rate	21%	21%	21%
State tax expense	7%	7.10%	0%
Stock-based compensation	1.70%	349.50%	0%
Change in fair value of assumed common stock warrant liabilities	0%	103.10%	(7.30%)
Research and development tax credit	2.70%	41.50%	0.20%
Permanent tax items	(0.10%)	(7.10%)	(0.20%)
State rate differential - change in apportionment	0%	4.40%	(0.10%)
Prior year deferred true-up	4.60%	2.50%	0.10%
Change in fair value of Series F tranche liabilities	0%	0%	(12.50%)
Sec. 162(m) wage limitation	(2.20%)	(113.90%)	(0.10%)
Change to valuation allowance	(34.70%)	(408.10%)	(1.10%)
Effective tax rate	0%	0%	0%

Income Taxes - Components of Ne

Income Taxes - Components of Net Deferred Tax Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Deferred tax assets:
Net operating losses	$ 336,617	$ 257,426
Tax credits	58,476	35,149
Accruals and stock-based compensation	28,152	10,479
Lease liability	30,571	20,234
Section 174 capitalized research & development	45,369
Intangibles		685
Gross deferred tax assets	499,185	323,973
Valuation allowance	(438,212)	(293,211)	$ (105,781)	$ (85,677)
Total deferred tax assets	60,973	30,762
Deferred tax liabilities:
Right of use assets	(24,450)	(18,999)
Intangibles	(561)
Fixed assets	(35,962)	(11,763)
Total deferred tax liabilities	$ (60,973)	$ (30,762)

Income Taxes - Reconciliation o

Income Taxes - Reconciliation of Beginning and Ending Balances of Valuation Allowance (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Beginning of the year	$ (293,211)	$ (105,781)	$ (85,677)
Increase	(145,001)	(187,430)	(20,104)
End of the year	$ (438,212)	$ (293,211)	$ (105,781)

Income Taxes - Reconciliation_2

Income Taxes - Reconciliation of Beginning and Ending Balances of Unrecognized Tax Benefits (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Beginning of the year	$ 32,172	$ 6,575	$ 7,076
Increase—current year positions	12,388	20,633	1,553
Decrease--current year positions	(5,056)
Increase—prior year positions	13,298	5,056	193
Decrease—prior year positions		(92)	(2,247)
End of the year	$ 52,802	$ 32,172	$ 6,575